image
imagewidth (px) 205
980
| latex
stringlengths 132
39.9k
| filename
stringlengths 18
19
|
|---|---|---|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Condition} & \textbf{Samples} & \textbf{Genotype} & \textbf{Treatment} & \textbf{Days after inoculation} & \textbf{Tissue} \\
\hline
T1 & 3 & nfr1 & R7A & 1d & SZ \\
\hline
T2 & 2 & nfr5 & R7A & 1d & SZ \\
\hline
T3 & 3 & nin & R7A & 1d & SZ \\
\hline
T4 & 3 & nup133 & R7A & 1d & SZ \\
\hline
T5 & 3 & WT & R7A & 1d & SZ \\
\hline
T6 & 2 & WT & purified Nod Factor & 1d & SZ \\
\hline
T7 & 3 & nfr1 & β & β & SZ \\
\hline
T8 & 3 & nfr5 & β & β & SZ \\
\hline
T9 & 3 & nin & β & β & SZ \\
\hline
T10 & 3 & nup133 & β & β & SZ \\
\hline
T11 & 3 & WT & β & β & SZ \\
\hline
T12 & 3 & WT & β & β & Root Tip \\
\hline
T13 & 3 & WT & R7A & 1d & Whole Root \\
\hline
T14 & 3 & WT & R7A nodC & 1d & Whole Root \\
\hline
T15 & 2 & WT & R7A & 3d & Whole Root \\
\hline
T16 & 3 & WT & R7A & 3d & Shoot \\
\hline
T17 & 2 & har1 & R7A & 3d & Whole Root \\
\hline
T18 & 3 & har1 & R7A & 3d & Shoot \\
\hline
T19 & 2 & har1 & β & β & Whole Root \\
\hline
T20 & 2 & har1 & β & β & Shoot \\
\hline
T21 & 3 & WT & β & β & Whole Root \\
\hline
T22 & 3 & WT & β & β & Shoot \\
\hline
T23 & 3 & WT & 5 mM Nitrate & β & Whole Root \\
\hline
T24 & 3 & WT & 5 mM Nitrate & β & Shoot \\
\hline
T25 & 2 & cyclops & β & β & Whole Root \\
\hline
T26 & 3 & sen1 & β & β & Whole Root \\
\hline
T27 & 2 & sst1 & β & β & Whole Root \\
\hline
T28 & 1 & cyclops & R7A & 21d & Root+Nodule \\
\hline
T29 & 3 & sen1 & R7A & 21d & Nodule \\
\hline
T30 & 3 & sst1 & R7A & 21d & Nodule \\
\hline
T31 & 3 & WT & R7A & 21d & Nodule \\
\hline
T32 & 3 & WT & R7A & 21d & Root+Nodule \\
\hline
T33 & 3 & WT & R7A & 14d & Nodule \\
\hline
T34 & 3 & WT & R7A & 7d & Root+Nodule \\
\hline
T35 & 3 & WT & 5 mM Nitrate for 6 weeks & β & Whole Root \\
\hline
T36 & 3 & WT & 5 mM Nitrate for 6 weeks & β & Leaf \\
\hline
T37 & 3 & WT & 5 mM Nitrate for 6 weeks & β & Stem \\
\hline
T38 & 3 & WT & 5 mM Nitrate for 13 weeks & β & Flower \\
\hline
\end{tabular}
\end{table} | PMC2717213_table_0 |
|
\begi\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{table}
\ce\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}teri\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}g
\label{tab:tablelabel}
\begi\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& & & \multicolum\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{2}{c|}{\textbf{Nodule}} & \multicolum\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{2}{c|}{\textbf{Root}} & \multicolum\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{2}{c|}{\textbf{Leaf}} & \multicolum\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{2}{c|}{\textbf{Stem}} & \multicolum\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}{2}{c|}{\textbf{Flower}} \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\textbf{biological \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess} & \textbf{GO term} & \textbf{All} & \textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}} \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& biosy\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}thetic \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess & 80 & & & & & 1 & 0.20 & & & 1 & 0.63 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& Cell differe\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}tiatio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & 62 & & & & & & & & & 1 & 0.53 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& cellular \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess & 3017 & 3 & 0.26 & 11 & 0.13 & 12 & 0.13 & 5 & 0.20 & 30 & 0.90 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& electro\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}s\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}ort & 278 & & & & & 4 & 0.01 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& macromolecule metabolic \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess & 5844 & 1 & 0.98 & 3 & 1.00 & 5 & 1.00 & 2 & 0.99 & 36 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& metabolic \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess & 634 & & & 3 & 0.21 & 5 & 0.03 & & & 12 & 0.09 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& multicellular orga\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}ismal develo\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}me\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}t & 304 & & & 1 & 0.54 & & & 1 & 0.27 & 8 & 0.03 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& regulatio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} of \textbf{biological \textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rocess} & 2308 & 1 & 0.76 & 10 & 0.06 & 4 & 0.89 & 6 & 0.03 & 22 & 0.91 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& res\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}o\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}se to stimulus & 2148 & 4 & 0.03 & 9 & 0.09 & 8 & 0.25 & 3 & 0.39 & 7 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& secretio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & 83 & & & 1 & 0.19 & & & & & 3 & 0.08 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
& tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}s\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}ort & 1080 & 1 & 0.48 & 5 & 0.14 & 6 & 0.08 & 1 & 0.68 & 26 & 0.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\multirow{7}{*}{cellular com\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}o\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}t} & cell & 587 & & & & & 1 & 0.81 & & & 6 & 0.72 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
chromosome & 106 & 1 & 0.06 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
cyto\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}lasm & 2574 & 2 & 0.46 & 1 & 1.00 & 5 & 0.85 & 3 & 0.51 & 18 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
exter\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}al e\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}ca\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}sulati\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}g structure & 127 & & & 3 & 0.00 & & & 1 & 0.12 & 14 & 0.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
extracellular regio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} & 23 & & & 1 & 0.06 & & & & & 2 & 0.03 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
membra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e & 2383 & 2 & 0.42 & 4 & 0.86 & 14 & 0.01 & 2 & 0.72 & 39 & 0.04 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}ucleus & 1493 & 1 & 0.60 & 1 & 0.98 & & & 3 & 0.20 & 3 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\multirow{19}{*}{molecular fu\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}ctio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}} & bi\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}di\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}g & 7710 & 2 & 0.97 & 15 & 0.91 & 18 & 0.84 & 4 & 0.98 & 75 & 0.99 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
catalytic activity & 1538 & & & & & 4 & 0.63 & & & 4 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
cha\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}el activity & 171 & & & 1 & 0.35 & 1 & 0.38 & & & 5 & 0.06 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
electro\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}s\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}orter activity & 87 & & & & & 2 & 0.02 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
e\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}zyme regulator activity & 311 & & & 1 & 0.55 & & & 1 & 0.28 & 11 & 0.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
hydrolase activity & 3758 & 4 & 0.17 & 12 & 0.23 & 9 & 0.73 & 3 & 0.77 & 85 & 0.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
io\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}smembra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}s\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}orter activity & 604 & 1 & 0.30 & 1 & 0.79 & 6 & 0.01 & 2 & 0.13 & 13 & 0.04 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
isomerase activity & 246 & & & & & & & & & 1 & 0.95 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
Ligase activity & 518 & & & & & 2 & 0.42 & & & 1 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
lyase activity & 426 & & & 2 & 0.29 & 2 & 0.33 & & & 9 & 0.08 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
motor activity & 176 & 1 & 0.10 & & & & & & & 3 & 0.36 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
oxidoreductase activity & 1299 & & & 14 & 0.00 & 7 & 0.07 & 3 & 0.15 & 16 & 0.52 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}rotei\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} bi\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}di\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}g & 1658 & & & 3 & 0.80 & 5 & 0.49 & 1 & 0.83 & 20 & 0.55 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
sig\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}al tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}sducer activity & 100 & & & & & 2 & 0.03 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
structural molecule activity & 455 & & & & & 1 & 0.72 & & & 1 & 1.00 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}scri\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}tio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} regulator activity & 2106 & 1 & 0.73 & 11 & 0.02 & 6 & 0.54 & 8 & 0.00 & 29 & 0.27 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}sferase activity & 5437 & 3 & 0.65 & 8 & 0.98 & 8 & 0.99 & 5 & 0.69 & 62 & 0.74 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}slatio\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}} regulator activity & 183 & & & & & & & & & 2 & 0.66 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
tra\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}s\textbf{\textbf{\textbf{\textbf{\textbf{p}}}}}orter activity & 978 & & & & & 8 & 0.01 & 1 & 0.64 & 15 & 0.22 \\
\hli\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}e
\e\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}d{tabular}
\e\textbf{\textbf{\textbf{\textbf{\textbf{n}}}}}d{table} | PMC2717213_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{ID} & \textbf{Cases} & \textbf{Age} & \textbf{Gender} & \textbf{Survival} & \textbf{History} & \textbf{Primary stage} & \textbf{Asbestos exposure years (y)} & \textbf{Smoking years (y)} \\
\hline
1 & C & 25 & M & & Recurrent right-sided pneumothorax, apical and lateral right superior lobe bullae. & T0N0M0 & 0 & 4 \\
\hline
2 & C & 16 & F & & Recurrent left-sided pneumothorax, apical bullae. & T0N0M0 & 0 & 0 \\
\hline
3 & C & 27 & M & & Recurrent right-sided pneumothorax, apical bullae. & T0N0M0 & 0 & 12 \\
\hline
4 & C & 51 & M & & Recurrent right-sided pneumothorax, multiple cysts superior lobe. & T0N0M0 & 0 & 34 \\
\hline
5 & C & 19 & M & & Recurrent right-sided pneumothorax, apical bullae & T0N0M0 & 0 & 1 \\
\hline
6 & C & 18 & M & & Left- then right-sided pneumothorax, apical bullae. & T0N0M0 & 0 & 0 \\
\hline
7 & T & 58 & M & 15 & Thoracic pain 6 months, then dyspnoea and expectorate, 6xCCG with partial remission, progression after 4xPC. & T2N2M1 & Unsure, possible ecological & 30 \\
\hline
8 & T & 42 & F & 69 & Dyspnoea 8 months, tumor in mediastinum, 6xCCG with partial remission, now 36xPC with excellent partial remission. & T4N3M0 & Hair-dryer with asbestos elements, 9 & 6 \\
\hline
9 & T & 71 & M & 11 & Pain right thorax and dyspnoea 4 months, 5 kg weight loss, 2xpegylated doxorubicin, progression, 4xPC with stable disease & T2N2M0 & Minimal & Not answered \\
\hline
10 & T & 50 & F & 6 & Large tumour of right thorax involving the breast and mediastinum, radiotherapy 3Gy x 13 because of vena cava superior syndrome, no effect, new biopsy 1 month later, 1xCCG with haematological toxicity grade IV. No more treatment indicated. & T4N3M1 & Unsure, worked in canning industry, old building & 35 \\
\hline
11 & T & 64 & M & 17 & 15 months breathless, weight loss 20 kg, blood-tinged pleural fluid, no pathological cells in pleural fluid after 3 months, tumour left pleura. 3xPC with progression, 6xCCG with clinical effect. & T2N1MX & 40 & 35 \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{ID} & \textbf{RNA} & \textbf{Histology P:positive, N:negative} \\
\hline
1 & PP two samples & Visceral pleura: Bullous emphysema*. Parietal pleura: Normal \\
\hline
2 & PP and PV & Visceral pleura: Bullous emphysema. Parietal pleura: Reactive fibrosis and normal \\
\hline
3 & PP & Visceral pleura: Bullous emphysema. Parietal pleura: ND \\
\hline
4 & PP and PV & Visceral pleura: Bullous emphysema fibrous thickening. Parietal pleura: Normal \\
\hline
5 & PP and PV & Visceral pleura: Bullous emphysema. Parietal pleura: Normal \\
\hline
6 & PP & Visceral pleura: Emphysematous bullae. Parietal pleura: Normal \\
\hline
7 & T & Epithelial type. P: Calretinin, EMA some positive cells, CK5/6. N: CEA, BerEp4, PSA, \\
\hline
8 & T & Epithelial type. P: Calretinin, EMA moderate, CK 7. N: CEA, BerEp4, S-100, Chromogranin, Thyreoglobulin, Calcitonin, TTF- 1, Synaptophysine, CK20 \\
\hline
9 & T & Epithelial type P: Calretinin, EMA, Pancytokeratin, CK5/6, Vimentin,MIB1 30\%. N: CEA, BerEp4 \\
\hline
10 & T from two locations & Epithelial type, grade 3. P: Calretinin, EMA, BerEp4 (focal), Pancytokeratin, N: CEA, CK20, Estrogen, Progesterone, Erbb2 \\
\hline
11 & T & Biphasic type P: Calretinin- small groups, EMA, CK7 focal, CK5/6 some positive cells, Vimentin, BerEp4-focal. N: CEA, CK20, TTF-1, PSA, PSF \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\multicolumn{8}{c|}{\textbf{\% of nucleated cells in each biopsy}} \\
\hline
\textbf{ID} & & \textbf{Epith. Comp mesothelioma} & \textbf{Sarc. Comp Mesothelioma} & \textbf{Mesothelium} & \textbf{Endothelium} & \textbf{Fibrocytes} & \textbf{Lymphocytes} \\
\hline
1 & PP & 0 & 0 & 10 & 40 & 40 & 2 \\
\hline
2 & PP & 0 & 0 & 1 & 30 & 50 & 2 \\
\hline
3 & PP & ND & ND & ND & ND & ND & ND \\
\hline
4 & PP & 0 & 0 & 1 & 20 & 50 & 1 \\
\hline
5 & PP & 0 & 0 & 5 & 20 & 15 & 24 \\
\hline
6 & PP & 0 & 0 & 15 & 40 & 20 & 10 \\
\hline
7 & T & 55 & 0 & ,1 & 2 & 4 & 25 \\
\hline
8 & T & 90 & 0 & 0 & 1 & 5 & 2 \\
\hline
9 & T & 90 & 0 & 0 & 3 & 1 & 2 \\
\hline
10 & T & 90 & 0 & 0 & ,1 & 3 & 2 \\
\hline
11 & T & 25 & 15 & ,1 & 5 & 10 & 15 \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{GO terms} & \textbf{Down Genes} & \textbf{Genes on Chip} & \textbf{Corrected P-values} \\
\hline
GO:0031224 intrinsic to membrane & 105 & 4176 & 1,18E-05 \\
\hline
GO:0050828 regulation of liquid surface tension & 4 & 5 & 0,0014 \\
\hline
GO:0007275 multicellular organismal development & 51 & 1984 & 0,0033 \\
\hline
GO:0004871 signal transducer activity & 43 & 1797 & 0,0344 \\
\hline
GO:0007155 cell adhesion & 21 & 664 & 0,0425 \\
\hline
GO:0045893 positive regulation of transcription, DNA-dependent & 11 & 201 & 0,0287 \\
\hline
GO:0006814 sodium ion transport & 8 & 108 & 0,0317 \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{GO term} & \textbf{Genes Up} & \textbf{Genes on Chip} & \textbf{Corrected P-value} & \textbf{Gene Symbols} \\
\hline
GO:0007049 cell cycle & 82 & 802 & 1,33E-15 \\
\hline
GO:0006260 DNA replication & 27 & 181 & 3,51E-08 & PHB,PCNA,TOP2A,RRM1,MCM3,MCM6, CDK2AP1,MCM2,TYMS,SSBP1,MSH6, RNASEH2A,RFC5,CDC6,RFC4,RBM14, FEN1,GINS1,GLI2,DNA2L,PRIM2,PTMSGTPBP, GMNN, ORC6L,GINS2,MCM4 \\
\hline
GO:0000087 M phase of mitotic cell cycle & 33 & 200 & 5,57E-11 & RAD21,RAN,RUVBL1,SMC4,BIRC5,CCNB2, TXNL4A,CDC20,BUB1B,CDC6,ZWINTNDC80, SMC2,CDC25A,KIF23,CENPF,AURKA,BRCA2, KIF2C,BUB1,CDC2,NUDC,NCAPD3,NUSAP1, CEP55,ASPM,CDC23,RCC2,CCNB1,CLASP1, CIT,HELLS,ESPL1 \\
\hline
GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process & 184 & 3337 & 1,62E-09 \\
\hline
GO:0005783 endoplasmic reticulum & 61 & 731 & 1,01E-08 \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{GO term} & \textbf{GenesDown} & \textbf{Genes On Chip} & \textbf{Corrected P-value} & \textbf{Gene Symbols} \\
\hline
GO:0007275 multicellular organismal development & 129 & 1984 & 2,08E-05 \\
\hline
GO:0048511 rhythmic process & 10 & 61 & 0,0254 & HLF,NR1D1,EGR2,EGR3,STAT5BCRY2, ANG,PER3,TEF, PER1 \\
\hline
GO:0030528 transcription regulator activity & 93 & 1300 & 2,33E-05 \\
\hline
GO:0045934 negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process & 28 & 290 & 0,0029 \\
\hline
GO:0007154 cell communication & 214 & 3326 & 1,80E-08 \\
\hline
GO:0007165 signal transduction & 197 & 3000 & 1,80E-08 \\
\hline
GO:0007264 small GTPase mediated signal transduction & 34 & 418 & 0,0080 \\
\hline
GO:0007155 cell adhesion & 59 & 664 & 1,45E-05 \\
\hline
GO:0006952 defense response & 49 & 500 & 1,45E-05 \\
\hline
GO:0006954 inflammatory response & 33 & 271 & 2,33E-05 \\
\hline
GO:0003707 steroid hormone receptor activity & 10 & 49 & 0,0069 & NR4A1,NR1D1,NR3C2,NR5A2, PGRMC2, NR4A2,NR1D2,PPARA, THRB,NR3C1 \\
\hline
\end{tabular}
\end{table} | PMC2717215_table_5 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Term} & \textbf{Definition} \\
\hline
Contact & First time an individual touches the foraging task with hand or mouth. \\
\hline
Unsuccessful Manipulation & An individual moves part of the task but does not eat. \\
\hline
Successful Manipulation & An individual extracts a raisin from the task. \\
\hline
Learning time & manipulationβ1. Difference in latency between an individualβs first βcontactβ and first βsuccessful \\
\hline
\end{tabular}
\end{table} | PMC2717327_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Control group (n = 28)} & \textbf{CVVH group (n = 29)} & \textbf{P value} \\
\hline
Age & 38 $\pm$ 18 & 27 $\pm$ 8 & 0.06 \\
\hline
Percentage TBSA & 58 $\pm$ 18 & 64 $\pm$ 18 & 0.21 \\
\hline
Percentage full thickness & 43 $\pm$ 27 & 49 $\pm$ 22 & 0.37 \\
\hline
Inhalation injury & 61\% & 41\% & 0.14 \\
\hline
ISS & 36 $\pm$ 14 & 35 $\pm$ 13 & 0.80 \\
\hline
APACHE II# & 36 $\pm$ 8 & 35 $\pm$ 5 & 0.76 \\
\hline
MODS# & 13 $\pm$ 4 & 12 $\pm$ 3 & 0.53 \\
\hline
SOFA# & 13 $\pm$ 4 & 13 $\pm$ 3 & 0.87 \\
\hline
AKIN stage 3 & 71\% & 70\% & 0.84 \\
\hline
BUN (mg/dl)* & 58 $\pm$ 26 & 46 $\pm$ 24 & 0.07 \\
\hline
Creatinine (mg/dl)* & 2.8 $\pm$ 1 & 2.9 $\pm$ 2 & 0.88 \\
\hline
Hospital day of T0 & 23 $\pm$ 26 & 17 $\pm$ 24 & 0.21 \\
\hline
Septic shock & 43\% & 42\% & 0.94 \\
\hline
Shock (all cause) & 68\% & 72\% & 0.50 \\
\hline
ALI/ARDS & 71\% & 55\% & 0.20 \\
\hline
\end{tabular}
\end{table} | PMC2717417_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Control group (n = 19)} & \textbf{CVVH group (n = 21)} & \textbf{P value} \\
\hline
Heart rate & 114 $\pm$ 20 & 121 $\pm$ 14 & 0.18 \\
\hline
MAP (mmHg) & 65 $\pm$ 13 & 61 $\pm$ 8 & 0.25 \\
\hline
CVP (cmH2O) & 18 $\pm$ 6 & 19 $\pm$ 8 & 0.85 \\
\hline
Norepinephrine dose (ΞΌg/min) & 4.2 $\pm$ 4.3 & 10.0 $\pm$ 12.6 & 0.06 \\
\hline
(ΞΌg/kg/min) Dopamine dose & 1.8 $\pm$ 3.6 & 0 & < 0.0001 \\
\hline
Vasopressin dose (units/min) & 0.016 $\pm$ 0.020 & 0.038 $\pm$ 0.009 & < 0.0001 \\
\hline
(ΞΌg/min) Neosynephrine dose & 4.9 $\pm$ 21.3 & 0 & < 0.0001 \\
\hline
(ΞΌg/kg/min) Dobutamine dose & 0.26 $\pm$ 1.1 & 7.6 $\pm$ 7.8 & < 0.001 \\
\hline
Mean lactate (mmol/L) & 2.9 $\pm$ 1.8 & 5.1 $\pm$ 4.2 & 0.12 \\
\hline
Steroids & 53\% & 33\% & 0.22 \\
\hline
\end{tabular}
\end{table} | PMC2717417_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Control group (T0)} & \textbf{Control group (T+24)} & \textbf{CVVH group (T0)} & \textbf{CVVH group (T+24)} \\
\hline
MAP (mmHg) & 65 $\pm$ 13 & 72 $\pm$ 13 & 61 $\pm$ 8 & 72 $\pm$ 6 \\
\hline
CVP (cmH2O) & 18 $\pm$ 5 & 22 $\pm$ 5 & 18 $\pm$ 6 & 19 $\pm$ 4 \\
\hline
Total fluids (liters) & 13 $\pm$ 4* & 13 $\pm$ 5 & 13 $\pm$ 5* & 11 $\pm$ 5 \\
\hline
Urine output (ml) & 1002 $\pm$ 657* & 942 $\pm$ 743 & 978 $\pm$ 754* & 688 $\pm$ 396 \\
\hline
Diuretic use (\%) & 5* & 25 & 6* & 0 \\
\hline
Weight (kg) & 84 $\pm$ 8 & 85 $\pm$ 7 & 84 $\pm$ 7 & 84 $\pm$ 6 \\
\hline
\end{tabular}
\end{table} | PMC2717417_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
& \textbf{All patients (n = 103)} \\
\hline
Age (years) & 58 $\pm$ 17 \\
\hline
Gender male/female, n/(\%) & 65 (63.1)/38 (36.9) \\
\hline
APACHE II score & 26 $\pm$ 7 \\
\hline
SOFA score & 9 $\pm$ 4 \\
\hline
Hemoglobin (g/dl) & 10.3 $\pm$ 1.9 \\
\hline
Presence of severe sepsis \\
\hline
Yes, n (\%) & 48 (46.6) \\
\hline
No, n (\%) & 55 (53.4) \\
\hline
Cardiogenic, n (\%) & 50 (48.5) \\
\hline
Vasoactive drug use \\
\hline
None, n (\%) & 41 (40) \\
\hline
Vasopressors, n (\%) & 33 (32) \\
\hline
Norepinephrine & 20 (19) \\
\hline
Dopamine & 5 (5) \\
\hline
Inotropes, n (\%) & 29 (28) \\
\hline
Dobutamine & 17 (17) \\
\hline
Milrinone & 5 (5) \\
\hline
Levosimendan & 2 (2) \\
\hline
Vasoactive dose \\
\hline
Norepinephrine, ΞΌg/kg/min & 0.1 $\pm$ 0.1 \\
\hline
ΞΌg/kg/min Dopamine, & 5.2 $\pm$ 2.6 \\
\hline
ΞΌg/kg/min Dobutamine, & 4.6 $\pm$ 1.9 \\
\hline
ΞΌg/kg/min Milrinone, & 0.42 $\pm$ 0.21 \\
\hline
ΞΌg/kg/min Levosimendan, & 0.2 $\pm$ 0.1 \\
\hline
\end{tabular}
\end{table} | PMC2717418_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Before intubation} & \textbf{After intubation} & \textbf{P value} \\
\hline
SaO2 (\%) & 90.6 $\pm$ 7.5 & 97.0 $\pm$ 2.9 & < 0.001 \\
\hline
O2ER (\%) & 32.1 $\pm$ 10.8 & 29.2 $\pm$ 11.6 & 0.002 \\
\hline
Heart rate (beats/min) & 103.7 $\pm$ 25.2 & 96.4 $\pm$ 23.1 & 0.020 \\
\hline
Respiratory rate (breaths/min) & 29.1 $\pm$ 6.2 & 15.2 $\pm$ 3.1 & < 0.001 \\
\hline
MAP (mmHg) & 67.8 $\pm$ 19.6 & 57.5 $\pm$ 21.1 & < 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717418_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \multirow{2}{*}{\textbf{ScvO2 (\%) Before intubation}} & \multirow{2}{*}{\textbf{After intubation}} & \multirow{2}{*}{\textbf{P value}} \\
\hline
\\
\hline
All patients & 61.8 $\pm$ 12.6 & 68.9 $\pm$ 12.2 & < 0.001 \\
\hline
Presence of severe sepsis \\
\hline
Yes (n = 48) & 63.6 $\pm$ 11.9 & 71.1 $\pm$ 12.0 & < 0.001 \\
\hline
No (n = 55) & 59.3 $\pm$ 13.1 & 65.6 $\pm$ 11.6 & < 0.001 \\
\hline
According to baseline ScvO2 \\
\hline
< 70\% (n = 76) & 56 $\pm$ 8.4 & 64.8 $\pm$ 10.8 & < 0.001 \\
\hline
$\geq$ 70\% (n = 27) & 78 $\pm$ 6.7 & 80.2 $\pm$ 8.1 & 0.181 \\
\hline
According to baseline SaO2 \\
\hline
< 90\% (n = 42) & 54.1 $\pm$ 8.0 & 61.5 $\pm$ 11.4 & < 0.001 \\
\hline
$\geq$ 90\% (n = 61) & 67.1 $\pm$ 12.5 & 73.0 $\pm$ 10.0 & < 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717418_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Characteristics} & \textbf{Value} \\
\hline
Patients, number & 21 \\
\hline
Male & 8 (38.1\%) \\
\hline
Female & 13 (61.9\%) \\
\hline
Age, years, median (min to max) & 57 (36 to 72) \\
\hline
Reason for medical ICU admission \\
\hline
Pneumonia & 12 (57.1\%) \\
\hline
Peritonitis & 4 (19.0\%) \\
\hline
Urinary tract infection & 2 (9.5\%) \\
\hline
Systemic mycosis & 2 (9.5\%) \\
\hline
Endocarditis & 1 (4.8\%) \\
\hline
Mediastinitis & 1 (4.8\%) \\
\hline
Mean arterial pressure (mmHg) & 78 (58 to 108) \\
\hline
Heart rate (beats/minute) & 95 (53 to 125) \\
\hline
Vasopressor support, number & 12 (57.1\%) \\
\hline
Mechanically ventilated, number & 19 (90.5\%) \\
\hline
Fraction of inspired oxygen (\%) & 40 (25 to 95) \\
\hline
APACHE II score & 22 (12 to 48) \\
\hline
SOFA score & 10 (3 to 19) \\
\hline
Mortality, number & 11 (52.4\%) \\
\hline
\end{tabular}
\end{table} | PMC2717419_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Reason for intubation} & \textbf{N} & \textbf{\%} \\
\hline
Pneumonia & 8 & 23 \\
\hline
Acute respiratory failure & 7 & 20 \\
\hline
Severe chest trauma & 3 & 9 \\
\hline
Interstitial lung disease & 2 & 6 \\
\hline
Cerebrovascular accident & 2 & 6 \\
\hline
Congestive heart failure & 2 & 6 \\
\hline
Acute respiratory distress syndrome & 2 & 6 \\
\hline
Pancreatitis & 2 & 6 \\
\hline
Head trauma & 2 & 6 \\
\hline
Others* & 5 & 14 \\
\hline
\end{tabular}
\end{table} | PMC2717423_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{RR < 20 breaths/minute (15 $\pm$ 3)}} & \multicolumn{3}{c|}{\textbf{RR > 20 breaths/minute (26 $\pm$ 5)}} \\
\hline
& \textbf{ADR < 2 (n = 23)} & \textbf{ADR > 2 (n = 14)} & \textbf{\textbf{value P}} & \textbf{ADR < 2 (n = 17)} & \textbf{ADR > 2 (n = 23)} & \textbf{\textbf{value P}} \\
\hline
Tidal volume (ml) & 577 $\pm$ 91 & 528 $\pm$ 101 & NS & 479 $\pm$ 109 & 483 $\pm$ 135 & NS \\
\hline
Oxygen saturation (\%) & 97 $\pm$ 3 & 97 $\pm$ 3 & NS & 97 $\pm$ 3 & 98 $\pm$ 2 & NS \\
\hline
Compliance (mL/mbar) & 60 $\pm$ 25 & 42 $\pm$ 12 & 0.058 & 51 $\pm$ 25 & 48 $\pm$ 20 & NS \\
\hline
Resistance (mbar L/second) & 15 $\pm$ 4 & 18 $\pm$ 7 & NS & 15 $\pm$ 3 & 16 $\pm$ 5 & NS \\
\hline
\end{tabular}
\end{table} | PMC2717423_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Age & Mean 58 years \\
\hline
Sex & 4 male:3 female \\
\hline
Diagnosis & 4 medical:3 surgical \\
\hline
APACHE II (admission) & Mean 18 \\
\hline
APACHE II (study) & Mean 17 \\
\hline
Days in intensive care unit & Mean 7 days \\
\hline
Serum creatinine (ΞΌmol/l) & Mean 73 ΞΌmol \\
\hline
Plasma albumin(g/l) & Mean 23 g/l \\
\hline
Feed tolerant1 & 5 of 6 tolerant of EN \\
\hline
Inotropes & 1 patient on catecholamine infusion \\
\hline
Parenteral nutrition & 0 of 7 \\
\hline
Weight & Mean 84 kgs \\
\hline
Rate of insulin infusion when ceased2 & Mean 2.0 U/hour \\
\hline
Total insulin dose in previous 24 hours & Mean 57 U/24 hours \\
\hline
\end{tabular}
\end{table} | PMC2717426_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Variables} & \textbf{CKD group} & \textbf{Control group} \\
\hline
Age (years) & 66.5 $\pm$ 14.3 & 74.8 $\pm$ 10.4 \\
\hline
Males/females & 66/70 & 13/20 \\
\hline
Aetiology of CKD \\
\hline
Diabetes & 80 (58.8\%) & - \\
\hline
Hypertension & 28 (20.6\%) & - \\
\hline
Chronic glomerulonephritis & 7 (5.1\%) & - \\
\hline
Others/unknown & 21 (15.4\%) & - \\
\hline
BUN (mg/dL) & 64.8 $\pm$ 34.9 & 22.2 $\pm$ 4.8 \\
\hline
Serum Cr (mg/dL) & 6.0 $\pm$ 4.1 & 0.9 $\pm$ 0.2 \\
\hline
eGFR (ml/min/1.73 m2) & 12.8 $\pm$ 7.3 & 71.4 $\pm$ 15.4 \\
\hline
BNP (pg/mL) & 1842.8 $\pm$ 1459.5 & 1418.9 $\pm$ 1126.5 \\
\hline
Haemodialysis/peritoneal dialysis & 47 (34.6\%)/11 (8.1\%) \\
\hline
Prior history \\
\hline
Congestive heart failure & 35 (25.7\%) & 7 (21.2\%) \\
\hline
Coronary artery disease & 39 (28.7\%) & 9 (27.2\%) \\
\hline
SAPS II & 41.9 $\pm$ 13.4 & 29.7 $\pm$ 4.0 \\
\hline
SOFA & 5.8 $\pm$ 2.9 & 3.3 $\pm$ 3.2 \\
\hline
Admission diagnosis \\
\hline
ADHF & 81 (59.6\%) & 33 (100\%) \\
\hline
Sepsis/infection & 12 (8.8\%) & - \\
\hline
Gastrointestinal/liver & 10 (7.4\%) & - \\
\hline
Neurological disease & 7 (5.1\%) & - \\
\hline
Others & 26 (19.1\%) & - \\
\hline
\end{tabular}
\end{table} | PMC2717430_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Variables} & \textbf{Correlation coefficients} & \textbf{P value} \\
\hline
Age & -0.146 & 0.090 \\
\hline
BUN & -0.063 & 0.464 \\
\hline
Serum Cr & 0.013 & 0.884 \\
\hline
Blood pressure \\
\hline
Systolic blood pressure & 0.297 & 0.001 \\
\hline
Diastolic blood pressure & 0.238 & 0.005 \\
\hline
Heart rate & 0.019 & 0.827 \\
\hline
C-reactive protein & -0.074 & 0.407 \\
\hline
WBC & -0.056 & 0.529 \\
\hline
Haemoglobin & -0.015 & 0.859 \\
\hline
Protein & 0.104 & 0.230 \\
\hline
Albumin & 0.023 & 0.793 \\
\hline
SAPS II & 0.025 & 0.777 \\
\hline
SOFA & 0.099 & 0.257 \\
\hline
Cardiac markers \\
\hline
CK & 0.067 & 0.454 \\
\hline
CK-MB & 0.056 & 0.529 \\
\hline
Troponin I & 0.066 & 0.460 \\
\hline
Echocardiographic data \\
\hline
LAD & 0.277 & 0.076* \\
\hline
LV diameter at end systole & 0.347 & 0.033* \\
\hline
LV diameter at end diastole & 0.283 & 0.066* \\
\hline
LV mass index & 0.526 & 0.000* \\
\hline
E/A ratio & -0.125 & 0.495* \\
\hline
Deceleration time & 0.198 & 0.303* \\
\hline
LVEF & -0.391 & 0.008* \\
\hline
Systolic dysfunction (EF <50\% vs. $\geq$ 50\%) & - & 0.032β \\
\hline
$\geq$ Diastolic dysfunction (grade II vs. <I) & - & 0.117β \\
\hline
vs. Mechanical ventilation (yes no) & - & 0.041# \\
\hline
\end{tabular}
\end{table} | PMC2717430_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Univariate anaysis} & \multicolumn{3}{c|}{\textbf{Multivariate analysis}} \\
\hline
\textbf{Variables} & \textbf{\textbf{P value}} & \textbf{\textbf{P value}} & \textbf{Odds ratios} & \textbf{95\% confidence intervals} \\
\hline
Age & 0.007 & 0.137 & 1.145 & 0.958 to 1.368 \\
\hline
Sex & 0.049 & 0.402 & 0.387 & 0.042 to 3.573 \\
\hline
BUN & 0.025 & 0.545 & 1.011 & 0.977 to 1.045 \\
\hline
Systolic blood pressure & 0.022 & 0.603 & 0.990 & 0.951 to 1.029 \\
\hline
Diastolic blood pressure & 0.019 & 0.227 & 0.966 & 0.912 to 1.022 \\
\hline
Albumin & 0.007 & 0.967 & 0.960 & 0.067 to 13.701 \\
\hline
C-reactive protein & 0.000 & 0.797 & 0.998 & 0.983 to 1.013 \\
\hline
CK & 0.078 & 0.061 & 1.003 & 1.000 to 1.006 \\
\hline
Systolic dysfunction (EF <50\%) & 0.085 & 0.208 & 5.125 & 0.402 to 65.388 \\
\hline
SAPS II & 0.000 & 0.556 & 0.936 & 0.749 to 1.168 \\
\hline
SOFA & 0.000 & 0.388 & 0.755 & 0.399 to 1.429 \\
\hline
MV treatment & 0.000 & 0.042 & 144.896 & 1.195 to 17573.2 \\
\hline
\end{tabular}
\end{table} | PMC2717430_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Univariate analysis} & \multicolumn{3}{c|}{\textbf{Multivariate analysis}} \\
\hline
\textbf{Variables} & \textbf{\textbf{P value}} & \textbf{\textbf{P value}} & \textbf{Hazard ratios} & \textbf{95\% confidence intervals} \\
\hline
WBC & 0.053 & 0.410 & 1.000 & 1.000 to 1.000 \\
\hline
Serum Cr & 0.044 & 0.046 & 0.855 & 0.734 to 0.997 \\
\hline
LVEF (\%) & 0.010 & 0.842 & 0.997 & 0.964 to 1.031 \\
\hline
LAD & 0.004 & 0.034 & 1.083 & 1.006 to 1.167 \\
\hline
LV mass index & 0.087 & 0.606 & 1.002 & 0.994 to 1.011 \\
\hline
C-reactive protein & 0.066 & 0.890 & 0.999 & 0.988 to 1.010 \\
\hline
ADHF & 0.038 & 0.780 & 0.816 & 0.197 to 3.385 \\
\hline
Admission BNP \\
\hline
Optimal cutoff level* & 0.007 & 0.078 & 4.551 & 0.845 to 24.502 \\
\hline
BNP (continuous variable) & 0.005 & 0.041 & 1.001 & 1.0002 to 1.0010 \\
\hline
BNP quartiles & 0.005 & 0.018 & 2.212 & 1.145 to 4.276 \\
\hline
\end{tabular}
\end{table} | PMC2717430_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Main effect} & \textbf{Beta estimate} & \textbf{Odds ratio 95\% CI} & \textbf{P value} \\
\hline
Intercept & -4.9419 & - & < 10-4 \\
\hline
Parameters on the day of severe sepsis \\
\hline
LOD (per point) & 0.1951 & 1.22 (1.16 to 1.27) & < 10-4 \\
\hline
Septic shock & 0.3335 & 1.40 (1.08 to 1.81) & 0.01 \\
\hline
First episode of severe sepsis & - & - & - \\
\hline
Second episode of severe sepsis & 0.2304 & 1.26 (0.96 to 1.66) & 0.10 \\
\hline
Third or fourth episode of severe sepsis & 0.9719 & 2.64 (1.71 to 4.08) & < 10-4 \\
\hline
Multiple sites of infection & 0.3734 & 1.45 (1.04 to 2.03) & 0.03 \\
\hline
Variables at ICU admission \\
\hline
SAPS (per point) & 0.0244 & 1.02 (1.01 to 1.03) & < 10-4 \\
\hline
Fatal illness by McCabe Score(score 2 or 3) & 0.6749 & 1.96 (1.43 to 2.70) & < 10-4 \\
\hline
No chronic illness & - & - & - \\
\hline
Exactly one chronic illness & 0.5592 & 1.75 (1.25 to 2.45) & 0.001 \\
\hline
Two or more chronic illnesses & 0.8084 & 2.24 (1.39 to 3.62) & 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717433_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Maximum} & \textbf{Minimum} & \textbf{Mean} & \textbf{SD} \\
\hline
CO value \\
\hline
PAC-CCO & 12.8 & 2.1 & 4.9 & 1.8 \\
\hline
NICOMβ’ & 13.1 & 1.4 & 4.8*β & 1.1 \\
\hline
Vigileoβ’ & 13.8 & 1.0 & 5.0 & 1.3 \\
\hline
Differences in CO \\
\hline
Vigileoβ’ β PAC-CCO & 8.9 & -7.8 & -0.1 & 1.2 \\
\hline
NICOMβ’ β PAC-CCO & 6.8 & -6.3 & 0.1β & 1.5 \\
\hline
NICOMβ’ β Vigileoβ’ & 8.6 & -9.1 & -0.1 & 1.8 \\
\hline
Relative errors \\
\hline
Vigileoβ’ & 1.97 & 0.0 & 0.19 & 0.17 \\
\hline
NICOMβ’ & 1.37 & 0.0 & 0.23β & 0.18 \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Maximum} & \textbf{Minimum} & \textbf{Mean} & \textbf{SD} \\
\hline
CO values \\
\hline
PAC-CCO & 8.7 & 2.5 & 4.8 & 1.4 \\
\hline
NICOMβ’ & 10.2 & 2.1 & 4.8 & 1.4 \\
\hline
FloTrac-Vigileoβ’ & 11.2 & 1.0 & 5.0* & 1.2 \\
\hline
Differences in CO \\
\hline
Vigileoβ’ β PAC-CCO & 4.8 & -3.0 & 0.1 & 0.9 \\
\hline
NICOMβ’ β PAC-CCO & 5.3 & -2.7 & 0.0β & 1.0 \\
\hline
NICOMβ’ β Vigileoβ’ & 4.1 & -5.1 & -0.1 & 1.2 \\
\hline
Relative errors \\
\hline
Vigileoβ’ & 0.97 & 0.0 & 0.16 & 0.12 \\
\hline
NICOMβ’ & 1.15 & 0.0 & 0.17β & 0.12 \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Systolic blood pressure} & \textbf{Bias} & \textbf{Relative error} \\
\hline
> 160 mmHg & 2.2 $\pm$ 1.5 L/min & 51 $\pm$ 36\% \\
\hline
120 to 160 mmHg & 0.6 $\pm$ 1.2 L/min. & 15 $\pm$ 27\% \\
\hline
80 to 120 mmHg & -0.1 $\pm$ 1.0 L/min & -0.0 $\pm$ 21\% \\
\hline
< 80 mmHg & -0.9 $\pm$ 1.3 L/min & -18 $\pm$ 25\% \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Pulmonary pressure} & \textbf{Bias} & \textbf{Relative error} \\
\hline
> 50 mmHg & 0.5 $\pm$ 1.3 L/min & 12 $\pm$ 31\% \\
\hline
40 to 50 mmHg, & 0.4 $\pm$ 1.4 L/min & 11 $\pm$ 30\% \\
\hline
< 50 mmHg, & 0.1 $\pm$ 1.5 L/min & 4 $\pm$ 30\% \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Hemoglobin (gr/L)} & \textbf{Bias} & \textbf{Relative error} \\
\hline
> 140 & 0.0 $\pm$ 1.0 L/min & 1 $\pm$ 24\% \\
\hline
100 to 140 & 0.3 $\pm$ 1.5 L/min & 7 $\pm$ 30\% \\
\hline
< 100 & -0.3 $\pm$ 1.4 L/min & -3 $\pm$ 28\% \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Time}} & \multicolumn{3}{c|}{\textbf{Amplitude}} \\
\hline
& \textbf{\textbf{PAC-CCO}} & \textbf{\textbf{NICOMβ’}} & \textbf{\textbf{Vigileoβ’}} & \textbf{\textbf{PAC-CCO}} & \textbf{\textbf{NICOMβ’}} & \textbf{\textbf{Vigileoβ’}} \\
\hline
Negative & 7.0 $\pm$ 2.6 & 1.3 $\pm$ 0.5* & 1.1 $\pm$ 0.3* & -2.9 $\pm$ 1.0 & -2.3 $\pm$ 0.8 & -1.8 $\pm$ 0.6 \\
\hline
Positive & 9.4 $\pm$ 4.9 & 1.4 $\pm$ 0.5* & 1.1 $\pm$ 0.3* & 2.0 $\pm$ 1.0 & 2.4 $\pm$ 1.4 & 1.8 $\pm$ 1.0 \\
\hline
\end{tabular}
\end{table} | PMC2717435_table_5 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Groups} & \textbf{Normal area (\%)} & \textbf{Alveolar collapse (\%)} & \textbf{MN (\%)} & P\textbf{MN (\%)} \\
\hline
C-SAL & 92.7 $\pm$ 0.7 & 7.3 $\pm$ 0.7 & 36.2 $\pm$ 0.4 & 7.8 $\pm$ 0.3 \\
\hline
C-Gln & 88.3 $\pm$ 1.8 & 11.7 $\pm$ 1.8 & 36.2 $\pm$ 0.4 & 7.7 $\pm$ 0.3 \\
\hline
CLP-SAL & 27.6 $\pm$ 3.0* & 72.4 $\pm$ 3.0* & 17.5 $\pm$ 1.5* & 42.2 $\pm$ 1.3* \\
\hline
CLP-Gln & 80.7 $\pm$ 2.6* # & 19.3 $\pm$ 2.6* # & 31.9 $\pm$ 0.6* # & 12.9 $\pm$ 0.7* # \\
\hline
\end{tabular}
\end{table} | PMC2717436_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Groups} & \textbf{Lung} & \textbf{Kidney} & \textbf{Liver} & \textbf{Villi} \\
\hline
C-SAL & 0.0 (0 to 1) & 0.0 (0 to 1) & 0.0 (0 to 1) & 0.0 (0 to 1) \\
\hline
C-Gln & 0.0 (0 to 1) & 0.5 (0 to 1) & 0.5 (0 to 1) & 0.0 (0 to 1) \\
\hline
CLP-SAL & 2.5 (2 to 4)* & 2.0 (2 to 3)* & 2.0 (2 to 3)* & 3.5 (3 to 4)* \\
\hline
CLP-Gln & 1.5 (1 to 2)* # & 1.0 (1 to 1)* # & 0.5 (0 to 1) & 0.0 (0 to 1) \\
\hline
\end{tabular}
\end{table} | PMC2717436_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Dexemedetomidine} & \textbf{Haloperidol} & \textbf{P} \\
\hline
N & 10 & 10 \\
\hline
Age, years: median (IQR) & 52 (42 to 69) & 68.5 (43 to 78) & 0.241 \\
\hline
Males: \% & 90 & 80 & 0.531 \\
\hline
A\textbf{P}ACHE II score in the 24 hours immediately prior to enrolment: median (IQR) & 13.3 (10 to 18) & 15.5 (11 to 19) & 0.383 \\
\hline
\textbf{P}hysical restraint prior to enrolment: \% & 80 & 50 & 0.160 \\
\hline
Midazolam use: \% & 60 & 40 & 0.371 \\
\hline
\textbf{P}ropofol use: \% & 70 & 70 & 1.000 \\
\hline
\textbf{Haloperidol} use: \% & 30 & 10 & 0.264 \\
\hline
Morphine use: \% & 80 & 80 & 1.000 \\
\hline
Other sedative or anti-psychotic use: \% & 0 & 0 \\
\hline
Time intubated prior to randomisation, hours: median (IQR) & 45.0 (34.5 to 73.3) & 65.2 (28.0 to 87.0) & 0.496 \\
\hline
RASS -2 to 1 (ie. desired level of sedation and agitation control) at enrolment: \% & 30 & 10 & 0.264 \\
\hline
ICDSC $\geq$ 4 (ie. delirium present) at enrolment: \% & 30 & 40 & 0.405 \\
\hline
$\geq$ ICDSC 4 at any stage prior to or during infusion of trial drug: \% & 50 & 50 & 1.00 \\
\hline
ICDSC > 0 (ie. at least subsyndromal delirium present) at enrolment: \% & 80 & 100 & 0.136 \\
\hline
ICDSC > 0 at any stage prior to or during infusion of trial drug: \% & 100 & 100 & 1.00 \\
\hline
Surgical diagnosis: \% & 70 & 30 & 0.074 \\
\hline
Admission diagnosis & & & 0.493 \\
\hline
\textbf{P}neumonia, \% & 0 & 20 \\
\hline
Other sepsis, \% & 20 & 20 \\
\hline
\textbf{P}ost cardiothoracic surgery, \% & 30 & 10 \\
\hline
\textbf{P}ost neurosurgery, \% & 30 & 20 \\
\hline
Other, \% & 20 & 30 \\
\hline
\end{tabular}
\end{table} | PMC2717438_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Dexemedetomidine} & \textbf{Haloperidol} & \textbf{P} \\
\hline
Time receiving study drug infusion while intubated, \%: median (IQR) & 100 (99.1 to 100.0) & 94.26 (68.9 to 100.0) & 0.2755 \\
\hline
Loading dose given, \% & 80 & 60 & 0.329 \\
\hline
Drug rate of infusion during the periods when it was administered: mean (95\% CI) & ΞΌg/kg/hour 0.47 (0.33 to 0.62) & 1.43 (0.96 to 1.90) mg/hour & N/A \\
\hline
Study drug continued after extubation, \% & 70 & 40 & 0.18 \\
\hline
Time study drug continued after extubation, hours: median (IQR) & 2.5 (0.0 to 26.0) & 0.0 (0.0 to 2.0) & 0.15 \\
\hline
Of patients who continued study drug after extubation, time continued, hours: median (IQR) & 15 (1 to 26) & 6.5 (2 to 16.5) & 0.57 \\
\hline
\end{tabular}
\end{table} | PMC2717438_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Dexmedetomidine} & \textbf{Haloperidol} & \textbf{P} \\
\hline
\textbf{P}rimary \\
\hline
Time to extubation, hours: median (IQR) & 19.9 (7.3 to 24.0) & 42.2 (23.2 to 117.8) & 0.016 \\
\hline
Secondary \\
\hline
Time to ICU discharge after randomisation, days: median (IQR) & 1.5 (1 to 3) & 6.5 (4 to 9) & 0.0039 \\
\hline
Total ICU length of stay, days: median (IQR) & 4.5 (2 to 7) & 8.0 (7.0 to 11.0) & 0.0093 \\
\hline
Time taken to achieve a satisfactory RASS agitation score (-2 to 1), hours: median (IQR) & 4 (0 to 7) & 18 (9 to 22) & 0.071 \\
\hline
Time taken to achieve a satisfactory ICDSC score (< 4), hours: median (IQR) & 0 (0 to 2) & 0 (0 to 2) & 0.509 \\
\hline
\textbf{P}roportion of time with a satisfactory RASS agitation score (-2 to 1), \%: median (IQR) & 50.5 (20 to 78) & 26.5 (13 to 42) & 0.256 \\
\hline
\textbf{P}roportion of time with a satisfactory ICDSC score (< 4) when assessable, \%: median (IQR) & 95.5 (51 to 100) & 31.5 (17 to 97) & 0.122 \\
\hline
\textbf{P}roportion of time with a desirable ICDSC score (< 1) when assessable, \%: median (IQR) & 61.0 (0.0 to 100.0) & 0.0 (0.0 to 0.0) & 0.134 \\
\hline
Required restraint at any time while on study drug, \% & 90 & 80 & 0.53 \\
\hline
Of patients requiring restraint at any time while on study drug, time to first not requiring restraint for > 4 hours, hours: median (IQR) & 18 (7.3 to 38.5) & 38 (26.3 to 49.8) & 0.03 \\
\hline
Need for supplemental sedative or analgesic medication, \% \\
\hline
\textbf{P}ropofol & 60 & 80 & 0.33 \\
\hline
Midazolam & 20 & 10 & 0.53 \\
\hline
Morphine & 30 & 40 & 0.64 \\
\hline
Of patients requiring supplemental sedative or analgesic medication, dose rate: mean (95\% CI) \\
\hline
\textbf{P}ropofol, mg/hour & 87.7 (15.5 to 160.0) & 123.4 (30.4 to 216.3) & 0.504 \\
\hline
Midazolam, mg/hour & 1.0 (1.0 to 1.0) & 2.4 (N/A) & N/A \\
\hline
Morphine, mg/hour & 1.0 (0.5 to 1.5) & 1.6 (0.3 to 2.8) & 0.28 \\
\hline
Of patients requiring supplemental sedative or analgesic medication, \% time this was required: mean (95\% CI) \\
\hline
\textbf{P}ropofol & 41.2 (0 to 88.2) & 79.5 (61.8 to 97.2) & 0.05 \\
\hline
Midazolam & 0 (0 to 0) & 0 (N/A) & N/A \\
\hline
Morphine & 0 (0 to 0) & 32.9 (0 to 100) & 0.29 \\
\hline
Required tracheostomy & 0 & 3 & 0.06 \\
\hline
\end{tabular}
\end{table} | PMC2717438_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Dexmedetomidine} & \textbf{Haloperidol} & \textbf{P} \\
\hline
ICU mortality, n & 0 & 0 & 1.00 \\
\hline
Hospital mortality, n & 0 & 1 & 0.31 \\
\hline
QTc interval prior to study drug, sec: mean (95\% CI) & 0.411 (0.384 to 0.438) & 0.426 (0.395 to 0.457) & 0.41 \\
\hline
QTc interval while on study drug, sec: mean (95\% CI) & 0.395 (0.365 to 0.425) & 0.446 (0.423 to 0.457) & 0.0061 \\
\hline
\textbf{P}atients with abnormal QTc interval (> 0.440 sec) while on study drug: \% & 40 & 40 & 1.00 \\
\hline
\textbf{P}atients with longer QTc interval than baseline while on study drug: \% & 30 & 70 & 0.07 \\
\hline
Arrhythmia while on study drug: \% & 20 & 20 & 1.00 \\
\hline
\textbf{P}atients requiring norepinephrine* infusion while on study drug: \% & 80 & 50 & 0.16 \\
\hline
\textbf{P}atients newly requiring norepinephrine or a 20\% increase in norepinephrine* infusion in the 8 hours after commencement of study drug: \% & 20 & 20 & 1.00 \\
\hline
Of patients requiring norepinephrine, proportion of the time while on study drug receiving norepinephrine: mean (95\%CI) & 59.8 (17.9 to 100.0) & 34.4 (0.0 to 87.1) & 0.37 \\
\hline
Of patients requiring norepinephrine, level of infusion (ΞΌg/min) while on study drug: mean (95\%CI) & 2.51 (0.07 to 4.90) & 3.97 (0.00 to 11.07) & 0.55 \\
\hline
Any adverse event attributed to the study drug: \% & 0 & 10** & 0.31 \\
\hline
\textbf{P}atients requiring reintubation: n, \% & 0 & 0 & 1.00 \\
\hline
\end{tabular}
\end{table} | PMC2717438_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Age, years (mean $\pm$ SD) & 48 ($\pm$ 12) \\
\hline
Female sex, n (\%) & 20 (65\%) \\
\hline
Body mass index (mean $\pm$ SD) & 22.8 ($\pm$ 3.2) \\
\hline
Body surface area, m2 (mean $\pm$ SD) & 1.70 ($\pm$ 0.17) \\
\hline
Fisher scale (1/2/3/4), n (\%) & 1 (3\%)/10 (32\%)/6 (20\%)/14 (45\%) \\
\hline
WFNS score (1/2/3/4/5), n (\%) & 14 (45\%)/9 (30\%)/2 (6\%)/2 (6\%)/4 (13\%) \\
\hline
Aneurysm position, n (\%) \\
\hline
ICA & 6 (19\%) \\
\hline
MCA & 9 (30\%) \\
\hline
AComA/ACA & 10 (32\%) \\
\hline
BA & 2 (6\%) \\
\hline
PCA & 1 (3\%) \\
\hline
VA & 3 (10\%) \\
\hline
\end{tabular}
\end{table} | PMC2717439_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
ECG abnormalities, n (\%) & 11 (36\%) \\
\hline
Coiled, n (\%) & 29 (94\%) \\
\hline
on day 1 & 23 \\
\hline
on day 2 & 5 \\
\hline
on day 6 & 1 \\
\hline
Craniotomy, n (\%) & 2 (6\%) \\
\hline
on day 1 & 2 \\
\hline
Vasospasm, n (\%) & 6 (19\%) \\
\hline
Rebleeding, n (\%) & 1 (3\%) \\
\hline
Hydrocephalus (derivated), n (\%) & 13 (42\%) \\
\hline
Norepinephrine (used during days 1β3) & 13 (42\%) \\
\hline
Mechanical ventilation (day 1/day 7), n (\%) & 15 (48\%)/5 (16\%) \\
\hline
\end{tabular}
\end{table} | PMC2717439_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Day 1} & \textbf{Day 2} & \textbf{Day 3} & \textbf{Day 4} \\
\hline
Natremia (mmol/L) & 140 $\pm$ 5 & 141 $\pm$ 7 & 142 $\pm$ 7 & 142 $\pm$ 8 \\
\hline
Fluid balance (mL) & -750 (-975 to 275) & -650 (-1475 to 650) & -500 (-1250 to 100) & -700 (-1100 to 400) \\
\hline
Sodium balance (mEq) & 136 (-59 to 221) & 1 (-102 to 182) & -34 (-136 to 136) & -51 (-144 to 41) \\
\hline
\end{tabular}
\end{table} | PMC2717439_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Day 1} & \textbf{Day 2} & \textbf{Day 7} \\
\hline
Systolic BP, mmHg & 128 ($\pm$ 10) & 136 ($\pm$ 11) & 132 ($\pm$ 29) \\
\hline
Diastolic BP, mmHg & 61 ($\pm$ 7) & 65 ($\pm$ 7) & 67 ($\pm$ 8) \\
\hline
Heart rate, beats/min & 76 ($\pm$ 11) & 76 ($\pm$ 11) & 82 ($\pm$ 10) \\
\hline
LV ejection fraction (\%) & 67 ($\pm$ 9) & 65 ($\pm$ 8) & 70 ($\pm$ 7) \\
\hline
LV end-systolic volume (ml) & 31 $\pm$ 5 & 31 $\pm$ 3 & 25 $\pm$ 5 \\
\hline
LV end-diastolic volume (ml) & 94 $\pm$ 16 & 90 $\pm$ 14 & 91 $\pm$ 18 \\
\hline
Systolic PAP, mmHg & 19 ($\pm$ 9) & 16 ($\pm$ 9) & 16 ($\pm$ 8) \\
\hline
LV mass (g/m2) & 111 ($\pm$ 25) & - & - \\
\hline
Mitral E (cm/s) & 88 ($\pm$ 21) & 96 ($\pm$ 22) & 83 ($\pm$ 16) \\
\hline
Mitral A (cm/s) & 67 ($\pm$ 20) & 68 ($\pm$ 20) & 70 ($\pm$ 20) \\
\hline
Mitral E/A ratio & 1.32 ($\pm$ 0.4) & 1.47 ($\pm$ 0.43) & 1.29 ($\pm$ 0.38) \\
\hline
Ea, lateral annulus (cm/s) & 17.1 ($\pm$ 6.5) & 17.2 ($\pm$ 4.8) & 16.3 ($\pm$ 3.2) \\
\hline
E/Ea & 5.4 ($\pm$ 1.5) & 5.8 ($\pm$ 1.2) & 5.1 ($\pm$ 0.9) \\
\hline
FPV (cm/s) & 74 ($\pm$ 15) & 77 ($\pm$ 12) & 77 ($\pm$ 10) \\
\hline
E/FPV & 1.27 ($\pm$ 0.4) & 1.25 ($\pm$ 0.3) & 1.1 ($\pm$ 0.2) \\
\hline
Deceleration time (ms) & 206 ($\pm$ 50) & 206 ($\pm$ 37) & 200 ($\pm$ 39) \\
\hline
Isovolumic relaxation time (ms) & 79 ($\pm$ 21) & 77 ($\pm$ 17) & 77 ($\pm$ 19) \\
\hline
\end{tabular}
\end{table} | PMC2717439_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \textbf{BNP day 1} & \textbf{BNP day 2} & \textbf{BNP day 3} & \textbf{BNP day 4} & \textbf{BNP day 5} & \textbf{BNP day 6} & \textbf{BNP day 7} \\
\hline
ΞΌg/L cTi <0.14 (n = 24) & 72 ($\pm$ 66) & 106 ($\pm$ 66) & 119 ($\pm$ 104) & 116 ($\pm$ 92) & 70 ($\pm$ 98) & 53 ($\pm$ 42) & 51 ($\pm$ 73) \\
\hline
ΞΌg/L cTi = 0.14 (n = 7) & 116 ($\pm$ 128) & 345 ($\pm$ 221)* & 271 ($\pm$ 323) & 113 ($\pm$ 97) & 111 ($\pm$ 113) & 122 ($\pm$ 130) & 101 ($\pm$ 129) \\
\hline
\end{tabular}
\end{table} | PMC2717439_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Variable} & \textbf{Canadian sites (n = 305)} \\
\hline
Gender, \% male & 57.7 \\
\hline
Mean age, years (SD) & 56.9 (17.2) \\
\hline
Mean APACHE II (SD) & 25.3 (7.8) \\
\hline
Mean number of organ dysfunctions (SD) & 3.1 (1.2) \\
\hline
Mean SOFA score (SD) & 10.9 (3.6) \\
\hline
Vasopressor use & 81.6\% \\
\hline
Mechanical ventilation & 90.5\% \\
\hline
\end{tabular}
\end{table} | PMC2717441_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Survivors Mean (SD)} & \textbf{Non-survivors Mean (SD)} & \textbf{P value*} \\
\hline
Age β years & 55.4 (17.4) & 62.3 (15.4) & 0.0014 \\
\hline
(ΞΌmol/L), Change in serum creatinine pre-infusion** to day 1 & 2.8 (85.7) & 31.0 (66.0) & 0.0011 \\
\hline
Change in platelet count (Γ 109/L) from pre-infusion to day 1 & -10.2 (47.7) & -27.6 (59.0) & 0.0052 \\
\hline
Number of organ dysfunctions per patient at baseline & 3.0 (1.16) & 3.4 (1.088) & 0.0073 \\
\hline
Baseline APACHE II score & 24.7 (7.65) & 27.4 (8.153) & 0.0100 \\
\hline
Time to treatment β hours & 26.1 (11.3) & 27.6 (14.0) & 0.2447 \\
\hline
Time to treatment <24 hours & 80.9\% & 19.1\% & 0.1788 \\
\hline
$\geq$24 Time to treatment hours & 74.4\% & 25.6\% \\
\hline
\end{tabular}
\end{table} | PMC2717441_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Age years} & \multicolumn{2}{c|}{\textbf{DrotAA <24 hours}} & \multicolumn{2}{c|}{\textbf{DrotAA $\geq$24 hours}} & \textbf{P value} \\
\hline
& \textbf{\textbf{n/N}} & \textbf{\textbf{\% Mortality}} & \textbf{\textbf{n/N}} & \textbf{\textbf{\% Mortality}} \\
\hline
$\leq$49 & 3/34 & 8.80 & 6/44 & 13.60 & 0.0409 \\
\hline
50 to 64 & 3/27 & 11.10 & 12/43 & 27.90 \\
\hline
65 to 74 & 5/24 & 20.80 & 9/25 & 36.00 \\
\hline
$\geq$75 & 6/22 & 27.27 & 8/23 & 34.78 \\
\hline
\end{tabular}
\end{table} | PMC2717441_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Variable} & \textbf{Odds ratio estimate (95\% CI)} & \textbf{P value} \\
\hline
Age, years \\
\hline
$\leq$49 vs 50 to 64 & 0.524 (0.2203 to 1.2461) & 0.144 \\
\hline
$\leq$49 vs 65 to 74 & 0.251 (0.102 to 0.617) & 0.003* \\
\hline
$\leq$49 vs $\geq$75 & 0.269 (0.106 to 0.678) & 0.005* \\
\hline
50 to 64 vs 65 to 74 & 0.479 (0.2146 to 1.0676) & 0.072 \\
\hline
$\geq$75 50 to 64 vs & 0.513 (0.2226 to 1.1802) & 0.116 \\
\hline
$\geq$75 65 to 74 vs & 1.071(0.4524 to 2.5346) & 0.876 \\
\hline
Time to treatment \\
\hline
Delay in time from first sepsis-induced organ dysfunction to start of study drug (six-hour intervals) & 1.231 (1.053 to 1.439) & 0.009* \\
\hline
Laboratory values \\
\hline
Increase in creatinine from baseline to day 1 (50 ΞΌmol/L intervals) & 1.317 (1.033 to 1.679) & 0.026* \\
\hline
Increase in platelets from baseline to day 1 (50 Γ 109/L unit intervals) & 0.658 (0.442 to 0.978) & 0.039* \\
\hline
\end{tabular}
\end{table} | PMC2717441_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{All patients (n = 1166)} & \textbf{AKI (n = 87)} & \textbf{Non AKI n = 1079} & \textbf{P} \\
\hline
Age in years, median (IQR) & 64 (53 to 73) & 68 (57 to 76) & 64 (53 to 73) & 0.002 \\
\hline
Age group, n (\%) & & & & 0.003 \\
\hline
$\geq$65 years & 581 (50) & 56 (64) & 525 (49) \\
\hline
< 65 years & 585 (50) & 31 (36) & 554 (51) \\
\hline
Sex, n (\%) & & & & 0.470 \\
\hline
Male & 761 (65) & 56 (64) & 705 (65) \\
\hline
Female & 405 (35) & 31 (36) & 374 (35) \\
\hline
ASA physical status & & & & < 0.001 \\
\hline
I/II/III & 1094 (94) & 68 (78) & 1026 (95) \\
\hline
IV/V & 72 (6) & 19 (22) & 53 (5) \\
\hline
Body mass index in Kg/m2, median (IQR) & 25 (22 to 28) & 24 (22 to 27) & 25 (22 to 28) & 0.020 \\
\hline
General anesthesia, n. (\%) & 940 (81) & 72 (85) & 868 (80) & 0.004 \\
\hline
Duration of anesthesia (min.) median (IQR) & 210 (150 to 300) & 200 (125 to 300) & 210 (150 to 300) & 0.772 \\
\hline
Temperature at admission on \textbf{P}ACU, mean $\pm$ sd & 35.23 $\pm$ 1.31 & 35.04 $\pm$ 1.70 & 35.25 $\pm$ 1.27 & 0.251 \\
\hline
Troponin I at admission, mean $\pm$ sd & 0.07 $\pm$ 0.32 & 0.18 $\pm$ 0.52 & 0.06 $\pm$ 0.29 & 0.011 \\
\hline
Hypertension, n (\%) & 565 (49) & 40 (46) & 525 (49) & 0.356 \\
\hline
Hyperlipidemia, n (\%) & 338 (29) & 24 (28) & 314 (29) & 0.438 \\
\hline
Emergency surgery & 231 (20) & 29 (33) & 202 (19) & 0.001 \\
\hline
High-risk surgery, n (\%) & 528 (45) & 63 (72) & 465 (43) & < 0.001 \\
\hline
Ischemic heart disease, n (\%) & 279 (24) & 33 (38) & 246 (23) & 0.001 \\
\hline
Congestive heart disease, n (\%) & 233 (20) & 40 (46) & 193 (18) & < 0.001 \\
\hline
Cerebrovascular disease, n (\%) & 170 (15) & 12 (11) & 158 (15) & 0.490 \\
\hline
Insulin therapy for diabetes, n (\%) & 104 (9) & 9 (10) & 95 (9) & 0.370 \\
\hline
Total RCRI & & & & < 0.001 \\
\hline
$\leq$2 & 437 (38) & 54 (62) & 833 (77) \\
\hline
> 2 & 729 (63) & 33 (28) & 246 (23) \\
\hline
Intraoperative fluid volume \\
\hline
Chrystaloids (L) (IQR) & 2.6 $\pm$ 1.8 (1.2 to 3.5) & 3.0 $\pm$ 2.3 (1.5 to 3.6) & 2.6 $\pm$ 1.7 (1.2 to 3.4) & 0.021 \\
\hline
Colloids (L) (IQR) & 0.2 $\pm$ 0.4 (0 to 0.5) & 0.3 $\pm$ 0.5 (0 to 0.5) & 0.2 $\pm$ 0.4 (0 to 0.5) & 0.014 \\
\hline
Erythrocytes (Units) (IQR) & 0.7 $\pm$ 1.6 (0 to 1) & 1.2 $\pm$ 2.6 (0 to 2) & 0.7 $\pm$ 1.5 (0 to 1) & 0.003 \\
\hline
Fresh frozen plasma (Units) (IQR) & 0.3 $\pm$ 1.0 (0 to 0) & 0.6 $\pm$ 1.5 (0 to 0) & 0.2 $\pm$ 1.0 (0 to 0) & 0.004 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{All patients (n = 1166)} & \textbf{AKI (n = 87)} & \textbf{Non AKI (n = 1079)} & \textbf{P} \\
\hline
SA\textbf{P}S II, median (IQR) & 18 (12 to 25) & 29 (20 to 45) & 18 (12 to 24) & < 0.001 \\
\hline
A\textbf{P}ACHE II, median (IQR) & 8 (5 to 11) & 12 (8 to 17) & 7 (5 to 10) & < 0.001 \\
\hline
\textbf{P}ACU length of stay (hours), median (IQR) & 25 (21 to 46) & 38 (22 to 72) & 25 (21 to 44) & < 0.001 \\
\hline
Hospital length of stay (days), median (IQR) & 13 (7 to 28) & 16 (8 to 32) & 13 (7 to 28) & 0.793 \\
\hline
Mortality in \textbf{P}ACU, n (\%) & 23 (2.0) & 17 (17.2) & 8 (0.7) & < 0.001 \\
\hline
Mortality in hospital, n (\%) & 50 (4.3) & 23 (26.4) & 27 (2.5) & < 0.001 \\
\hline
Mortality at six months follow-up, n (\%) & 134 (11.5) & 31 (35.6) & 103 (9.5) & < 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\multirow{2}{*}{\textbf{Variable}} & \multirow{2}{*}{\textbf{AKI/non AKI n = 87/n = 1079}} & \multirow{2}{*}{\textbf{Odds ratio (95\% CI)}} & \multirow{2}{*}{\textbf{P}} \\
\hline
\\
\hline
Age & 66.9 $\pm$ 13.2/61.5 $\pm$ 15.5 & 1.03 (1.01 to 1.04) & 0.002 \\
\hline
$\geq$65 years & 56 (64)/525 (49) & 1.91 (1.21 to 3.00) & 0.005 \\
\hline
< 65 years & 31 (36)/554(51) & 1 \\
\hline
Gender & & 0.96 (0.61 to 1.51) & 0.855 \\
\hline
Female & 31 (36)/374 (35) \\
\hline
Male & 56 (64)/705 (65) \\
\hline
Body mass index, median & 24.0 $\pm$ 4.3/25.6 $\pm$ 5.8 & 0.94 (0.89 to 1.00) & 0.019 \\
\hline
Duration of anesthesia (min.) & 233 $\pm$ 140/230 $\pm$ 113 & 1.00 (0.99 to 1.00) & 0.772 \\
\hline
General/Combined anesthesia, n. (\%) & 72 (85)/868 (80) & 4.59 (1.43 to 14.71) & 0.010 \\
\hline
Emergency surgery & 29 (33)/202 (19) & 2.17 (1.36 to 3.49) & 0.001 \\
\hline
ASA physical status \\
\hline
II/III & 68(78)/1026 (95) & 1 \\
\hline
IV/V & 19 (22)/53 (5) & 5.41 (3.03 to 9.65) & < 0.001 \\
\hline
Temperature at admission & 35.1 $\pm$ 1.8/35.2 $\pm$ 1.3 & 0.91 (0.78 to 1.07) & 0.251 \\
\hline
Troponin at admission & 0.20 $\pm$ 0.57/0.06 $\pm$ 0.29 & 1.81 (0.95 to 3.44) & 0.070 \\
\hline
Hypertension & 40(46)/525 (49) & 0.90 (0.58 to 1.39) & 0.631 \\
\hline
Hyperlipidemia & 24 (28)/314(29) & 0.93 (0.57 to 1.50) & 0.765 \\
\hline
High-risk surgery & 63 (72)/465 (43) & 3.47 (2.13 to 5.63) & < 0.001 \\
\hline
Ischemic heart disease & 33 (38)/246 (23) & 2.07 (1.31 to 3.26) & 0.002 \\
\hline
Congestive heart disease & 40 (46)/193 (18) & 3.91 (2.49 to 6.12) & < 0.001 \\
\hline
Cerebrovascular disease & 12(14)/158 (15) & 0.93 (0.50 to 1.76) & 0.829 \\
\hline
Insulin therapy for diabetes & 9 (10)/95 (9) & 1.20 (0.58 to 2.46) & 0.628 \\
\hline
RCRI \\
\hline
$\leq$2 & 54 (62)/833 (77) & 1 \\
\hline
> 2 & 33 (38)/246 (23) & 3.30 (2.12 to 5.14) & < 0.001 \\
\hline
Intraoperative fluid volume \\
\hline
Crystalloids (L) & 3.0 $\pm$ 2.3/2.6 $\pm$ 1.7 & 1.14 (1.02 to 1.28) & 0.024 \\
\hline
Colloids (L) & 0.3 $\pm$ 0.5/0.2 $\pm$ 0.4 & 1.76 (1.11 to 2.78) & 0.016 \\
\hline
Erythrocytes (Units) & 1.2 $\pm$ 2.6/0.7 $\pm$ 1.5 & 1.15 (1.04 to 1.27) & 0.005 \\
\hline
Fresh frozen plasma (Units) & 0.6 $\pm$ 1.5/0.2 $\pm$ 1.0 & 1.22 (1.04 to 1.42) & 0.012 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\multirow{2}{*}{\textbf{Variable}} & \multirow{2}{*}{\textbf{AKI/non AKI n = 87/n = 1079}} & \multirow{2}{*}{\textbf{Odds ratio (95\% CI)}} & \multirow{2}{*}{\textbf{P}} \\
\hline
\\
\hline
SA\textbf{P}S II & 33.3 $\pm$ 18.7/18.9 $\pm$ 10.3 & 1.08 (1.06 to 1.10) & < 0.001 \\
\hline
A\textbf{P}ACHE II & 13.0 $\pm$ 6.8/8.0 $\pm$ 4.3 & 1.18 (1.14 to 1.23) & < 0.001 \\
\hline
\textbf{P}ACU stay (days) & 2.8 $\pm$ 3.4/1.8 $\pm$ 2.1 & 1.14 (1.06 to 1.21) & < 0.001 \\
\hline
Hospital stay (days) & 25 $\pm$ 27/24 $\pm$ 32 & 1.00 (0.99 to 1.01) & 0.793 \\
\hline
Mortality in the \textbf{P}ACU & 17 (17)/8 (1) & 27.89 (11.45 to 67.96) & < 0.001 \\
\hline
Mortality in the hospital & 23 (26)/27 (3) & 14.00 (7.60 to 25.79) & < 0.001 \\
\hline
Mortality at 6 months & 31 (36)/103 (10) & 5.25 (3.24 to 8.51) & < 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{Beta} & \textbf{Adjusted OR} & \textbf{p} \\
\hline
ASA \textbf{p}hysical status & 1.371 & 3.94 (2.07 to 7.51) & < 0.001 \\
\hline
RCRI & 0.896 & 2.45 (1.52 to 3.96) & < 0.001 \\
\hline
High-risk-surgery & 1.206 & 3.34 (2.02 to 5.53) & < 0.001 \\
\hline
Congestive Heart disease & 0.851 & 2.34 (1.42 to 3.88) & 0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{Simple OR} & \textbf{P} & \textbf{Adjusted* OR (95\% CI)} & \textbf{P}a \\
\hline
Age group, n (\%) \\
\hline
$\geq$65 years & 2.69 & 0.002 \\
\hline
< 65 years & 1 \\
\hline
ASA physical status \\
\hline
I/II/III & 1 & & 1 \\
\hline
IV/V & 15.12 & < 0.001 & 5.17 (2.38 to 11.21) & < 0.001 \\
\hline
Temperature & 0.71 & < 0.001 \\
\hline
Emergency surgery & 4.05 & < 0.001 \\
\hline
High-risk surgery & 3.26 & < 0.001 & 2.15 (1.02 to 4.53) & 0.043 \\
\hline
Congestive heart disease & 6.75 & < 0.001 & 2.90 (1.45 to 5.76) & 0.002 \\
\hline
SA\textbf{P}S II & 1.09 & < 0.001 & 1.06 (1.03 to 1.08) & < 0.001 \\
\hline
A\textbf{P}ACHE II & 1.27 & < 0.001 \\
\hline
\textbf{P}ACU LOS (days) & 1.19 & < 0.001 \\
\hline
AKI & 14.00 & < 0.001 & 3.12 (1.41 to 6.93) & 0.005 \\
\hline
\end{tabular}
\end{table} | PMC2717442_table_5 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Patient} & \textbf{Aetiology} & \textbf{Brain Pathology} & \textbf{Measurements made on (day after TBI)} & \textbf{Number of hours studied on ICU} & \textbf{β n} & \textbf{AIS} & \textbf{ISS} \\
\hline
A & Fall & ICH & 3 & 5 & 13 & 4 & 17 \\
\hline
B & Fall & Bilateral frontal haematoma & 5, 6 & 5 & 17 & 5 & 30* \\
\hline
C & Fall & SDH & 3, 5 & 5 & 14 & 4 & 16 \\
\hline
D & Fall & DAI & 4 & 5 & 11 & 5 & 26 \\
\hline
E & RTA & Temporal contusions & 6, 7 & 5 & 20 & 4 & 16 \\
\hline
F & RTA & DAI & 2, 3 & 5 & 26 & 5 & 45* \\
\hline
G & Fall & ICH & 2 & 5 & 12 & 5 & 25 \\
\hline
H & Assault & SDH & 5, 6 & 5 & 23 & 4 & 17 \\
\hline
I & Assault & Temporal contusions & 2 & 5 & 9 & 3 & 18* \\
\hline
J & Fall & SDH & 2 & 5 & 10 & 4 & 16 \\
\hline
K & RTA & SDH & 3 & 5 & 11 & 4 & 16 \\
\hline
L & Fall & SDH, SAH, cerebral contusions & 4 & 5 & 21 & 5 & 42* \\
\hline
M & RTA & SDH, cerebral oedema & 4 & 5 & 21 & 4 & 24* \\
\hline
N & RTA & Cerebral oedema, SAH, contusions & 5 & 5 & 21 & 4 & 21* \\
\hline
O & Fall & Cerebral contusions & 4 & 5 & 21 & 4 & 16 \\
\hline
P & RTA & DAI & 2 & 5 & 19 & 5 & 66* \\
\hline
Q & RTA & Cerebral oedema & 4 & 5 & 21 & 3 & 17* \\
\hline
R & Fall & EDH, cerebral oedema, cerebral contusions & 3 & 5 & 21 & 4 & 16 \\
\hline
S & RTA & SDH, cerebral contusions & 2 & 5 & 21 & 4 & 41* \\
\hline
T & RTA & SAH, cerebral contusions & 2, 3 & 5 & 21 & 4 & 18* \\
\hline
\end{tabular}
\end{table} | PMC2717446_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Pig number} & \textbf{Weight (kg)} & \textbf{VT (mL)} & \textbf{Rf (breaths.min)} & \textbf{V' (L/s)} & \textbf{PEEPt (cmH2O)} & \textbf{Pplat (cmH2O)} & \textbf{PaO2 * (mmHg)} & \textbf{PaCO2 * (mmHg)} & \textbf{pH*} & \textbf{MAP (mmHg)} \\
\hline
1 & 31 & 310 & 18 & 0.28 & 0.7 & 11.4 & 100 & 37 & 7.43 & 85 \\
\hline
2 & 30 & 300 & 20 & 0.30 & 0.0 & 16.0 & 85 & 38 & 7.44 & 84 \\
\hline
3 & 24 & 250 & 26 & 0.36 & 0.0 & 15.0 & 80 & 35 & 7.38 & 86 \\
\hline
4 & 30 & 300 & 17 & 0.28 & 0.0 & 14.0 & 122 & 28 & 7.53 & 90 \\
\hline
5 & 26 & 260 & 20 & 0.26 & 0.0 & 8.5 & 124 & 36 & 7.41 & 69 \\
\hline
6 & 30 & 270 & 23 & 0.35 & 0.3 & 14.0 & 101 & 37 & 7.42 & 89 \\
\hline
Mean & 28 & 282 & 21 & 0.31 & 0.17 & 13.2 & 102 & 35 & 7.44 & 84 \\
\hline
SD & 3 & 25 & 3 & 0.04 & 0.29 & 2.7 & 18 & 4 & 0.05 & 8 \\
\hline
\end{tabular}
\end{table} | PMC2717448_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Controls} & \textbf{\textbf{P}CT-guided antibiotic therapy} & \textbf{P} \\
\hline
\textbf{P}atients (n) & 53 & 57 \\
\hline
Age (years) & 66.6 $\pm$ 15.5 & 67.3 $\pm$ 14.4 & >0.05 \\
\hline
Gender & & & >0.05 \\
\hline
Male & 29 & 29 \\
\hline
Female & 24 & 28 \\
\hline
Diagnoses & & & >0.05 \\
\hline
\textbf{P}neumonia & 19 & 24 \\
\hline
\textbf{P}eritonitis & 30 & 29 \\
\hline
Soft tissue infection & 1 & 2 \\
\hline
Urosepsis & 3 & 2 \\
\hline
SA\textbf{P}S II & 40.5 $\pm$ 15.1 & 40.1 $\pm$ 17.1 & >0.05 \\
\hline
Intensive care (days) & 17.7 $\pm$ 10.1 & 15.5 $\pm$ 12.5 & 0.046 \\
\hline
Hospital discharge & & & >0.05 \\
\hline
Survived & 39 & 42 \\
\hline
Deceased & 14 & 15 \\
\hline
\end{tabular}
\end{table} | PMC2717450_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Controls} & \textbf{\textbf{P}CT-guided antibiotic therapy} & \textbf{P} \\
\hline
Antibiotic classes (\%) & & & >0.05 \\
\hline
Acylaminopenicillin + BLI & 51.8 & 55.2 \\
\hline
Acylaminopenicillin + nitroimidazole & 19.6 & 15.5 \\
\hline
Carbapenem & 8.8 & 10.4 \\
\hline
Aminobenzylpenicillin + BLI & 5.4 & 6.9 \\
\hline
Fluorochinolone & 5.4 & 5.2 \\
\hline
Cephalosporins of Group 3b & 5.4 & 3.4 \\
\hline
Others & 3.6 & 3.4 \\
\hline
Length of antibiotic therapy (days) & 7.9 $\pm$ 0.5 & 5.9 $\pm$ 1.7 & <0.001 \\
\hline
\end{tabular}
\end{table} | PMC2717450_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\multicolumn{3}{c|}{\textbf{Ξ pressure}} & \multicolumn{2}{c|}{\textbf{5 cmH20}} & \multicolumn{2}{c|}{1\textbf{5 cmH20}} \\
\hline
& & \textbf{Effort} & \multirow{2}{*}{\textbf{low 10.5 $\pm$ 0.9}} & \multirow{2}{*}{\textbf{high 12.1 $\pm$ 0.2}} & \multirow{2}{*}{\textbf{low 14.6 $\pm$ 2.9}} & \multirow{2}{*}{\textbf{high 15.6 $\pm$ 2.4}} \\
\hline
\textbf{Normal lung condition} & \textbf{Paw mean (cmH2O)} & \textbf{HF-BiPAP nBBIPAPBiPulse} \\
\hline
& & BiVent & 10.6 $\pm$ 1.2 & 11.8 $\pm$ 1.8 & 15.3 $\pm$ 2.8 & 15.5 $\pm$ 2.2 \\
\hline
& PTPPEEP. (cmH20/sec) & HF-BiPAP & -0.1 $\pm$ 0.1 & -0.2 $\pm$ 0.2 & -0.2 $\pm$ 0.1 & -0.1 $\pm$ 0.1 \\
\hline
& & BiVent & 0 $\pm$ 0 & -0.2 $\pm$ 0.1 & 0 $\pm$ 0 & -0.3 $\pm$ 0.2 \\
\hline
& PTP insp. (cmH20/sec) & HF-BiPAP & 1.2 $\pm$ 0.8 & 1.1 $\pm$ 0.7 & 3.3 $\pm$ 2.6 & 4 $\pm$ 1.7 \\
\hline
& & BiVent & 1.3 $\pm$ 1.2 & 1.8 $\pm$ 1.5 & 2.7 $\pm$ 1.7 & 3.5 $\pm$ 2.4 \\
\hline
& PTP exp. (cmH20/sec) & HF-BiPAP e & 7 $\pm$ 6.1 & 3.8 $\pm$ 1.8 & 10 $\pm$ 6.4 & 4.2 $\pm$ 1.8 \\
\hline
& & BiVent & 7.2 $\pm$ 3.2 & 7.0 $\pm$ 0.9 & 11.8 $\pm$ 3.9 & 4.6 $\pm$ 1.8 \\
\hline
\multirow{8}{*}{Obstructive lung condition} & \textbf{Paw mean (cmH2O)} & HF-BiPAP & 10.4 $\pm$ 1 & 10.4 $\pm$ 0.7 & 15 $\pm$ 3.8 & 16.3 $\pm$ 3.4 \\
\hline
& BiVent & 10.3 $\pm$ 2.3 & 11 $\pm$ 3.5 & 15.4 $\pm$ 7.2 & 15.4 $\pm$ 4.1 \\
\hline
PTPPEEP. (cmH20/sec) & HF-BiPAP & 0 $\pm$ 0 & -0.13 $\pm$ 0.15 & -0.01 $\pm$ 0.05 & -0.05 $\pm$ 0.16 \\
\hline
& BiVent & 0 $\pm$ 0 & -0.2 $\pm$ 0.01 & -0.02 $\pm$ 0.04 & -0.2 $\pm$ 0.24 \\
\hline
PTP insp. (cmH20/sec) & HF-BiPAP & 1.0 $\pm$ 0.9 & 2.04 $\pm$ 1.4 & 3.6 $\pm$ 2.6 & 3.6 $\pm$ 2 \\
\hline
& BiVent & 1.3 $\pm$ 1.1 & 2.5 $\pm$ 2.4 & 2.8 $\pm$ 2.1 & 3.1 $\pm$ 2.7 \\
\hline
PTP exp. (cmH20/sec) & HF-BiPAP & 3.8 $\pm$ 2.5 & 9.8 $\pm$ 4.8 & 2.9 $\pm$ 1.7 & 10.1 $\pm$ 8.1 \\
\hline
& BiVent & 7.2 $\pm$ 3.2 & 10.9 $\pm$ 4.1 & 3.8 $\pm$ 1.9 & 10.3 $\pm$ 3.8 \\
\hline
\multirow{8}{*}{Restrictive lung condition} & \textbf{Paw mean (cmH2O)} & HF-BiPAP & 10.5 $\pm$ 1 & 11.7 $\pm$ 0.1 & 14.7 $\pm$ 2.2 & 14.7 $\pm$ 2.3 \\
\hline
& BiVent & 9.9 $\pm$ 1 & 11.1 $\pm$ 1 & 15 $\pm$ 2.8 & 15.4 $\pm$ 4.7 \\
\hline
PTPPEEP. (cmH20/sec) & HF-BiPAP & -0.16 $\pm$ 0.2 & -0.1 $\pm$ 0.2 & 0.09 $\pm$ 0.1 & -0.09 $\pm$ 0.1 \\
\hline
& BiVent & -0.35 $\pm$ 0.4 & -0.24 $\pm$ 0.2 & -0.16 $\pm$ 0.2 & -0.16 $\pm$ 0.2 \\
\hline
PTP insp. (cmH20/sec) & HF-BiPAP & 1 $\pm$ 0.6 & 1.2 $\pm$ 0.2 & 3.3 $\pm$ 2 & 3.4 $\pm$ 2 \\
\hline
& BiVent & 2 $\pm$ 1.5 & 1.4 $\pm$ 0.9 & 3.3 $\pm$ 2.9 & 1.9 $\pm$ 2.4 \\
\hline
PTP exp. (cmH20/sec) & HF-BiPAP & 3.7 $\pm$ 1.7 & 7.8 $\pm$ 3.7 & 4.2 $\pm$ 2.4 & 9.4 $\pm$ 4.5 \\
\hline
& BiVent & 5 $\pm$ 1 & 7.2 $\pm$ 4.9 & 7.5 $\pm$ 3.2 & 10.1 $\pm$ 5.5 \\
\hline
\end{tabular}
\end{table} | PMC2717454_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Patient number} & \textbf{N\textbf{I}SS} & \multicolumn{\textbf{3}}{c|}{\textbf{MODS score Admission, \textbf{2}\textbf{4} hours, 7\textbf{2} hours}} & \textbf{Outcome after 90 days} & \textbf{\textbf{I}njury pattern} \\
\hline
\textbf{I} & \textbf{\textbf{3}\textbf{3}} & \textbf{4} & \textbf{3} & \textbf{2} & \textbf{neurological deficits upper extremity} & \textbf{subtotal amputation upper limb, bilateral pulmonary contusion, minor scalp laceration} \\
\hline
\textbf{I}\textbf{I} & \textbf{\textbf{3}\textbf{3}} & \textbf{3} & 5 & \textbf{2} & deceased due to MOF & moderate H\textbf{I}, pulmonary contusion, subtotal amputation lower extremity \\
\hline
\textbf{I}\textbf{I}\textbf{I} & \textbf{2}0 & 6 & 8 & 5 & complete recovery & pulmonary contusion, blunt abdominal trauma \\
\hline
\textbf{I}V & 17 & \textbf{2} & \textbf{3} & 1 & complete recovery & minor H\textbf{I}, pulmonary contusion, fx upper extremity, multiple fx lower ext. \\
\hline
V & \textbf{2}\textbf{2} & \textbf{2} & \textbf{4} & \textbf{3} & complete recovery & displaced trimalleolar fx, unilateral pulmonary contusion, lumbar vertebral body fx \\
\hline
V\textbf{I} & \textbf{2}\textbf{4} & \textbf{4} & 6 & \textbf{3} & rehabilitation hospital & minor H\textbf{I}, pulmonary contusion, serial rib fx, pelvic fx \\
\hline
V\textbf{I}\textbf{I} & \textbf{2}9 & 5 & 5 & \textbf{2} & complete recovery & bilateral pulmonary contusion, serial rib fx, sinistral femur shaft fx, \textbf{I}\textbf{I}\textbf{I} open tibia fx \\
\hline
V\textbf{I}\textbf{I}\textbf{I} & 57 & 6 & 8 & 7 & neurological deficits due to H\textbf{I} & severe H\textbf{I}, pulmonary contusion, cardiac contusion, serial rib fx, cervical spine fx, liver rupture \\
\hline
\textbf{I}X & \textbf{3}\textbf{4} & \textbf{3} & 5 & \textbf{3} & disabled by missing right upper extremity, no neurological deficits & moderate H\textbf{I}, pulmonary contusion, cervical spine fx, traumatic amputation in the upper extremity shoulder joint, open book pelvic fx, multiple fx lower extremities \\
\hline
X & \textbf{3}6 & 5 & 8 & 5 & disabled by significant neurological deficits due to the brain injury & severe H\textbf{I}, intracerebral bleeding, bilateral pulmonary contusion, sinistral serial rib fx C\textbf{2}-10, hemopneumothorax, spleen hematoma \\
\hline
X\textbf{I} & \textbf{3}\textbf{4} & 6 & 8 & \textbf{4} & complete recovery & thoracic trauma, cardiac contusion, blunt abdominal trauma, liver rupture, renal contusion, cervical spine fx, bilateral fx upper extremities \\
\hline
X\textbf{I}\textbf{I} & \textbf{4}1 & \textbf{4} & 6 & \textbf{3} & disabled by significant neurological deficits due to the brain injury & moderate H\textbf{I}, cranial fx (Le fort \textbf{I}\textbf{I}\textbf{I}), pulmonary contusion, serial rib fx, pelvic fx, multiple open fx lower extremities \\
\hline
X\textbf{I}\textbf{I}\textbf{I} & \textbf{3}8 & \textbf{4} & 7 & \textbf{4} & physical therapy & moderate H\textbf{I}, cranial fx (Le fort \textbf{I}\textbf{I}\textbf{I}), lower limb fx \\
\hline
\end{tabular}
\end{table} | PMC2717459_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Time post trauma} & \textbf{Admission} & \textbf{6 hours} & \textbf{12 hours} & \textbf{24 hours} & \textbf{48 hours} & \textbf{72 hours} \\
\hline
Monocytes \% & 5.6 $\pm$ 3.4 & 6.5 $\pm$ 1.1 & 5.7 $\pm$ 2.6 & 5.8 $\pm$ 0.9 & 5.7 $\pm$ 2.0 & 6.2 $\pm$ 0.8 \\
\hline
CD14 (MFI) & 78.4 $\pm$ 10.7 & 81.3 $\pm$ 11.3 & 79.3 $\pm$ 9.8 & 74.7 $\pm$ 13.5 & 79.8 $\pm$ 9.8 & 76.5 $\pm$ 13.1 \\
\hline
\end{tabular}
\end{table} | PMC2717459_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Study} & \textbf{Patients} & \textbf{Design and setting} & \textbf{Exposure} & \textbf{Mean pre- transfusion Hb/Hct} & \textbf{Analysis (variables)} & \textbf{Main result} \\
\hline
β‘Kramer and colleagues [28] & 245 & Retrospective Single-center & - Anemia (nadir Hb <10 g/dl) - RBC transfusion (35\%) & 9.5 g/dl No transfusion protocol & Logistic regression (WFNS score, age, vasospasm, modified Fisher score) & - Anemia and transfusion associated with poor 6 week outcome (association stronger for transfusion) - RBCs associated with nosocomial infection - Age of blood not associated with complications \\
\hline
β‘Kramer and colleagues [154] & 245 & Retrospective Single-center & Daily nadir Hb over 2 weeks & 9.5 g/dl No transfusion protocol & GEE to account for correlated data (WFNS score, age, vasospasm, modified Fisher score) & - Hb and decline in Hb over time predict poor outcome - Association between Hb and outcome stronger among high grade patients \\
\hline
β Naidech and colleagues [155] & 611 & Retrospective (prospective database) Single-center & - Mean and nadir Hb over 2 weeks - 35\% transfused & Not reported No transfusion protocol & Multinomial regression (Hunt-Hess, age, cerebral infarction) & Higher nadir (but not mean) Hb associated with better outcome after 3 months (OR = 0.83 per 10 g/dl increase; P = 0.04) \\
\hline
Naidech and colleagues [156] & 103 & Retrospective (prospective database) Single-center & - Mean Hb over 2 weeks - 47\% transfused & 9.2 g/dl No transfusion protocol & Logistic regression (Hunt-Hess, age, angiographic vasospasm) & Higher 2 week mean Hb associated with better outcome at discharge (OR = 0.57 per 10 g/dl increase; P = 0.04) \\
\hline
Tseng and colleagues [157] & 160 & Post hoc analysis 2 RCTs) Single-center & RBC transfusion (19\%) & Not reported & Logistic regression (age, WFNS, IVH, postoperative deficits, sepsis, DIDs) & - Transfusion associated with poor outcome at discharge (OR = 4.5, P = 0.04) but not 6 months - More colloid use predicted lower hct and need for transfusion \\
\hline
β Wartenberg and colleagues [158] & 576 & Retrospective (prospective database) Single-center & Anemia (Hb <9 g/ dl treated with transfusion; 36\% of cohort) & Not reported No transfusion protocol & Logistic regression (Hunt-Hess, age, cerebral infarction, re-bleeding, aneurysm size >10 mm) & Anemia associated with worse 3 month outcome (OR = 1.8; P = 0.02) \\
\hline
* DeGeorgia and colleagues [159] & 166 & Retrospective Single-center & RBC Transfusion (49\%) & Not reported No transfusion protocol & Logistic regression (Hunt-Hess, APACHE II) & Transfusion associated with worse outcome at discharge among patients with vasospasm, not without (OR = 2.9, CI = 1.1 to 7.8) \\
\hline
Smith and colleagues [160] & 441 & Retrospective (prospective database) Single-center & RBC transfusion (61\%) & Intra- operative: 39.6\% Post- operative: 32.0\% No transfusion protocol & Logistic regression (Hunt-Hess, Fisher, smoking, intra-operative rupture, delay to surgery) & - Intraoperative transfusion associated with poor 6 month outcome (OR = 2.4, CI = 1.3 to 4.5) - Postoperative transfusion associated with angiographic vasospasm (OR = 1.7, CI = 1.0 to 2.8)) \\
\hline
\end{tabular}
\end{table} | PMC2717460_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Study} & \textbf{Patients} & \textbf{Design and setting} & \textbf{Exposure} & \textbf{Outcome} & \textbf{Main result} & \textbf{Comment} \\
\hline
Sacco and colleagues [174] & 3481 ischemic stroke & Retrospective (prospective data- base) Multi-center & Baseline hct (patients divided into quartiles) & Death at 28 days & Hct >46\% associated with death, but only among women & $\leq$40\% Hct represented lowest quartile; effects of more extreme anemia not reported \\
\hline
Diamond and colleagues [175] & 1012 ischemic stroke & Retrospective Single-center & Baseline hct Median 41\%; inter-quartile range 38 to 44\% & Discharge home (rather than nursing facility) & High and low hct associated with worse outcome (U shaped curve) Optimal hct 45\% & Only 2\% of patients had hct <30\% at time of their stroke \\
\hline
Lowe and colleagues [177] & 270 ischemic stroke & Retrospective Single-center & Baseline hct & Death in hospital & \textbf{Patients} with high hct ($\geq$50\%) had higher mortality (66 to 71\%) & Elderly ($\geq$75) with hct <40\% also had higher mortality (65\%) \\
\hline
Allport and colleagues [178] & 64 hemispheric ischemic stroke & Prospective Single-center & Baseline hct Median 42\%; range 33 to 48\% & Reperfusion, infarct growth on serial MRI & Higher hct associated with less reperfusion (OR = 0.53, P < 0.0001) and more infarct growth (OR = 1.26, P < 0.05) & This was a study of the effects of high hct; few patients were anemic \\
\hline
β Huang and colleagues [179] & 774 ischemic stroke & Prospective Single-center & Anemia (Hb <13 g/dl for men, <12 g/dl for women) (21\%) & Death and mRS $\geq$3 at 3 years & Anemic patients more likely to die (OR = 2.2, P = 0.02) and to have a poor neurological outcome (67\% vs. 60\%, P = 0.07) & Numerous potential confounders not adjusted for; severity of anemia not well characterized \\
\hline
β Huang and colleagues [180] & 66 ischemic stroke (complicating ICA occlusion) & Prospective Single center & Anemia (Hb <13 for men, <12 for women) & Death or recurrent stroke at 2 years & Anemia associated with death or recurrent stroke at 2 years (OR = 5.1, P = 0.012) & Numerous potential confounders not adjusted for; severity of anemia not well characterized \\
\hline
Nybo and colleagues [181] & 250 ischemic stroke & Retrospective Single-center & Anemia (Hb <13 g/dl for men, <12 g/dl for women) (15\%) & Death at 6 months & Anemia associated with greater risk of death (OR = 3.6, CI = 1.4 to 9.3) & Numerous potential confounders not adjusted for; severity of anemia not well characterized \\
\hline
Bhatia and colleagues [182] & 116 ischemic or hemorrhagic stroke & Retrospective Single-center & Baseline Hb & Death at 30 days & Hb not associated with risk of death & Degree of anemia relatively mild \\
\hline
Wade and colleagues [183] & 1377 symptomatic cerebrovascular disease & Retrospective (post hoc review of prospective RCT) Multi-center & Hb >15 g/dl vs. $\geq$15 g/dl at study entry & Stroke & \textbf{Patients} with Hb $\geq$15 had similar outcomes to patients with Hb <15 g/dl & This was a study of the effects of high Hb; few patients were anemic \\
\hline
LaRue and colleagues [184] & 2077 ischemic or hemorrhagic stroke & Retrospective (prospective database) Multi-center & Baseline hct (patients divided into quartiles) & Death in hospital & Hct not predictive of death (neither when high nor low) & Neurologic outcomes (other than death) not reported \\
\hline
\end{tabular}
\end{table} | PMC2717460_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Age, years & 72 $\pm$ 12 \\
\hline
Gender, \% male & 55 \\
\hline
SOFA score & 9.8 $\pm$ 2.8 \\
\hline
APACHE II score & 24.4 $\pm$ 5.4 \\
\hline
APACHE II predicted risk mortality & 50.8 $\pm$ 17.5 \\
\hline
Actual mortality, \% & 50 \\
\hline
Source of sepsis, n (\%) \\
\hline
Pneumonia & 9 (45) \\
\hline
Intra-abdominal infection & 3 (15) \\
\hline
Primary bacteremia & 3 (15) \\
\hline
Endovascular infection & 2 (10) \\
\hline
Cellulitis & 2 (10) \\
\hline
Urinary tract infection & 1 (5) \\
\hline
Fluid balance on the previous day, ml & 4592 $\pm$ 3156 \\
\hline
Fluid administration on the previous day, ml & 6183 $\pm$ 2601 \\
\hline
\end{tabular}
\end{table} | PMC2717464_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Mean arterial blood pressure}} & \textbf{ANOVA} & \textbf{Linear trend} \\
\hline
& \textbf{65 mmHg} & \textbf{75 mmHg} & \textbf{85 mmHg} & \textbf{\textbf{P}} & \textbf{\textbf{P}} \\
\hline
(ΞΌg/kg/min) Norepinephrine doses & 0.48 $\pm$ 0.43 & 0.65 $\pm$ 0.68* & 0.74 $\pm$ 0.67* & < 0.0001 & < 0.0001 \\
\hline
Heart rate (beats/min) & 94 $\pm$ 21 & 92 $\pm$ 18 & 93 $\pm$ 18 & 0.59 & 0.43 \\
\hline
\textbf{Mean arterial blood pressure} (mmHg) & 65 $\pm$ 2 & 76 $\pm$ 2* & 85 $\pm$ 2* & < 0.0001 & < 0.0001 \\
\hline
Mean pulmonary artery pressure (mmHg) & 28 $\pm$ 7 & 30 $\pm$ 7* & 30 $\pm$ 7* & < 0.0001 & < 0.0001 \\
\hline
\textbf{\textbf{P}}ulmonary artery occlusion pressure (mmHg) & 14 $\pm$ 4 & 15 $\pm$ 4 & 16 $\pm$ 4 & 0.06 & 0.02 \\
\hline
Central venous pressure (mmHg) & 11 $\pm$ 4 & 12 $\pm$ 4 & 12 $\pm$ 4 & 0.18 & 0.47 \\
\hline
Cardiac index (l/min/m2) & 2.98 $\pm$ 0.99 & 3.11 $\pm$ 1.07 & 3.23 $\pm$ 1.02* & 0.0002 & < 0.0001 \\
\hline
Oxygen transport (ml/min/m2) & 366 $\pm$ 137 & 379 $\pm$ 145 & 383 $\pm$ 166 & 0.53 & 0.28 \\
\hline
Oxygen consumption (ml/min/m2) & 100 $\pm$ 33 & 91 $\pm$ 31 & 90 $\pm$ 40 & 0.61 & 0.63 \\
\hline
Intramucosal-arterial pCO2 (mmHg) & 15 $\pm$ 15 & 16 $\pm$ 18* & 16 $\pm$ 18 & 0.03 & 0.06 \\
\hline
\end{tabular}
\end{table} | PMC2717464_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Mean arterial blood pressure}} & \textbf{ANOVA} & \textbf{Linear trend} \\
\hline
& \textbf{65 mmHg} & \textbf{75 mmHg} & \textbf{85 mmHg} & \textbf{\textbf{P}} & \textbf{\textbf{P}} \\
\hline
Arterial lactate (mmol/L) & 2.6 $\pm$ 2.8 & 2.4 $\pm$ 2.7 & 2.5 $\pm$ 2.7 & 0.27 & 0.32 \\
\hline
Hemoglobin (g\%) & 9.6 $\pm$ 2.3 & 9.6 $\pm$ 2.4 & 9.6 $\pm$ 2.3 & 0.76 & 0.79 \\
\hline
Arterial pH & 7.26 $\pm$ 0.11 & 7.26 $\pm$ 0.11 & 7.26 $\pm$ 0.11 & 0.44 & 0.29 \\
\hline
Arterial \textbf{\textbf{P}}CO2 (mmHg) & 39 $\pm$ 10 & 39 $\pm$ 10 & 40 $\pm$ 11 & 0.73 & 0.57 \\
\hline
Arterial \textbf{\textbf{P}}O2 (mmHg) & 112 $\pm$ 48 & 113 $\pm$ 45 & 108 $\pm$ 34 & 0.39 & 0.25 \\
\hline
Arterial HCO3- (mmol/l) & 18 $\pm$ 5 & 18 $\pm$ 5 & 18 $\pm$ 5 & 0.50 & 0.43 \\
\hline
Arterial oxygen saturation & 0.96 $\pm$ 0.02 & 0.96 $\pm$ 0.02 & 0.96 $\pm$ 0.03 & 0.67 & 0.44 \\
\hline
Mixed venous pH & 7.23 $\pm$ 0.11 & 7.24 $\pm$ 0.10 & 7.24 $\pm$ 0.10 & 0.78 & 0.49 \\
\hline
Mixed venous \textbf{\textbf{P}}CO2 (mmHg) & 45 $\pm$ 11 & 45 $\pm$ 11 & 45 $\pm$ 11 & 0.90 & 0.69 \\
\hline
Mixed venous \textbf{\textbf{P}}O2 (mmHg) & 42 $\pm$ 7 & 43 $\pm$ 7 & 44 $\pm$ 8* & 0.04 & 0.02 \\
\hline
Mixed venous HCO3- (mmol/l) & 19 $\pm$ 5 & 19 $\pm$ 5 & 19 $\pm$ 5 & 0.18 & 0.08 \\
\hline
Mixed venous oxygen saturation & 0.70 $\pm$ 0.08 & 0.72 $\pm$ 0.08* & 0.73 $\pm$ 0.07* & 0.01 & 0.005 \\
\hline
Central venous oxygen saturation & 0.74 $\pm$ 0.08 & 0.76 $\pm$ 0.08* & 0.77 $\pm$ 0.08* & 0.01 & 0.004 \\
\hline
Arterial anion gap (mmol/L) & 18 $\pm$ 6 & 19 $\pm$ 6 & 20 $\pm$ 7 & 0.16 & 0.06 \\
\hline
\end{tabular}
\end{table} | PMC2717464_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{c|}{\textbf{Mean arterial blood pressure}} & \textbf{ANOVA} & \textbf{Linear trend} \\
\hline
& \textbf{65 mmHg} & \textbf{75 mmHg} & \textbf{85 mmHg} & \textbf{\textbf{P}} & \textbf{\textbf{P}} \\
\hline
Vascular density (vessels/mm2) \\
\hline
Large diameter vessels & 11 $\pm$ 1 & 10 $\pm$ 3 & 10 $\pm$ 3 & 0.81 & 0.61 \\
\hline
Medium diameter vessels & 15 $\pm$ 3 & 16 $\pm$ 4 & 16 $\pm$ 4 & 0.82 & 0.53 \\
\hline
Small diameter vessels & 24 $\pm$ 8 & 23 $\pm$ 8 & 22 $\pm$ 1 & 0.09 & 0.03 \\
\hline
Microvascular flow index \\
\hline
Large diameter vessels & 2.3 $\pm$ 0.6 & 2.3 $\pm$ 0.8 & 2.2 $\pm$ 0.8 & 0.34 & 0.16 \\
\hline
Medium diameter vessels & 2.2 $\pm$ 0.7 & 2.2 $\pm$ 0.7 & 2.1 $\pm$ 0.9 & 0.79 & 0.52 \\
\hline
Small diameter vessels & 2.1 $\pm$ 0.7 & 2.2 $\pm$ 0.7 & 2.0 $\pm$ 0.8 & 0.69 & 0.47 \\
\hline
\textbf{\textbf{P}}erfused vessels (\%) \\
\hline
Large diameter vessels & 82 $\pm$ 21 & 80 $\pm$ 28 & 87 $\pm$ 6 & 0.46 & 0.40 \\
\hline
Medium diameter vessels & 77 $\pm$ 27 & 77 $\pm$ 29 & 77 $\pm$ 6 & 0.98 & 1.00 \\
\hline
Small diameter vessels & 72 $\pm$ 26 & 71 $\pm$ 27 & 67 $\pm$ 32 & 0.55 & 0.38 \\
\hline
Total vessels & 75 $\pm$ 25 & 75 $\pm$ 27 & 76 $\pm$ 4 & 0.92 & 0.73 \\
\hline
Heterogeneity flow index \\
\hline
Large diameter vessels & 1.0 $\pm$ 0.5 & 1.3 $\pm$ 1.2 & 1.5 $\pm$ 1.4 & 0.07 & 0.02 \\
\hline
Medium diameter vessels & 1.6 $\pm$ 1.6 & 1.5 $\pm$ 1.4 & 1.7 $\pm$ 1.2 & 0.86 & 0.78 \\
\hline
Small diameter vessels & 1.8 $\pm$ 1.3 & 1.8 $\pm$ 1.2 & 1.7 $\pm$ 1.1 & 0.97 & 0.80 \\
\hline
\end{tabular}
\end{table} | PMC2717464_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Septic group} \\
\hline
Demographic data \\
\hline
Age, years & 65.9 $\pm$ 12.4 (range = 28 to 97; median = 68; interquartile range = 60 to 74) \\
\hline
Male sex & 60 (59.4\%) \\
\hline
Primary site of infection/septic focus \\
\hline
Lung & 59 (58.4\%) \\
\hline
Gastrointestinal tract & 4 (4.0\%) \\
\hline
Genitourinary tract & 11 (10.9\%) \\
\hline
Surgical site & 7 (6.9\%) \\
\hline
Other & 11 (10.9\%) \\
\hline
Unknown & 9 (8.9\%) \\
\hline
Outcome \\
\hline
Survivor & 52 (51.5\%) \\
\hline
Postoperative group \\
\hline
Demographic data \\
\hline
Age, years & 62.3 $\pm$ 14.2 (range = 37 to 84; median = 64; interquartile range = 51.5 to 73) \\
\hline
Male sex & 15 (53.6\%) \\
\hline
Primary site of surgery \\
\hline
Pancreas & 13 (46.4\%) \\
\hline
Colon & 5 (17.9\%) \\
\hline
Liver & 2 (7.1\%) \\
\hline
Genitourinary & 3 (10.7\%) \\
\hline
Other abdominal & 5 (17.9\%) \\
\hline
Volunteer group \\
\hline
Demographic data \\
\hline
Age, years & 34.5 $\pm$ 8.6 \\
\hline
Male sex & 10 (55.6\%) \\
\hline
\end{tabular}
\end{table} | PMC2717465_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Healthy (n = 18)} & \textbf{Postoperative (n = 28)} & \textbf{Sepsis (n = 101)} \\
\hline
IL-6 (pg/ml) & 0.0; 0.0 to 0.8 & 216.7; 48.8 to 360.5 & 160.5; 58.8 to 448.8 \\
\hline
P values & \multicolumn{3}{c|}{Healthy vs. Postoperative: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Healthy vs. Sepsis: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Postoperative vs. Sepsis: P = 0.604} \\
\hline
sICAM-1 (ng/ml) & 219.6; 195.2 to 285.1 & 213.7; 192.3 to 293.8 & 444.7; 330.3 to 665.5 \\
\hline
P value & \multicolumn{3}{c|}{Healthy vs. Postoperative: P = 0.819} \\
\hline
& \multicolumn{3}{c|}{Healthy vs. Sepsis: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{P Postoperative vs. Sepsis: < 0.001***} \\
\hline
sVCAM-1 (ng/ml) & 1524.7; 991.2 to 2038.0 & 1268.0; 1167.7 to 1550.8 & 1147.9; 883.5 to 2047.4 \\
\hline
P value & \multicolumn{3}{c|}{Healthy vs. Postoperative: P = 0.545} \\
\hline
& \multicolumn{3}{c|}{Healthy vs. Sepsis: P = 0.280} \\
\hline
& \multicolumn{3}{c|}{Postoperative vs. Sepsis: P = 0.450} \\
\hline
Total CK-18 (U/l) & 241.9; 216.9 to 285.3 & 558.7; 465.6 to 793.0 & 1643.8; 1096.5 to 2633.5 \\
\hline
P value & \multicolumn{3}{c|}{Healthy vs. Postoperative: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{P Healthy vs. Sepsis: < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Postoperative vs. Sepsis: P < 0.001***} \\
\hline
CK-18 fragments (U/l) & 143.7; 134.4 to 168.1 & 116.0; 106.6 to 165.1 & 392.6; 258.4 to 654.5 \\
\hline
P value & \multicolumn{3}{c|}{Healthy vs. Postoperative: P = 0.250} \\
\hline
& \multicolumn{3}{c|}{Healthy vs. Sepsis: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Postoperative vs. Sepsis: P < 0.001***} \\
\hline
Ratio & 0.58; 0.55 to 0.67 & 0.22; 0.18 to 0.25 & 0.24; 0.14 to 0.35 \\
\hline
P value & \multicolumn{3}{c|}{P Healthy vs. Postoperative: < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Healthy vs. Sepsis: P < 0.001***} \\
\hline
& \multicolumn{3}{c|}{Postoperative vs. Sepsis: P = 0.507} \\
\hline
\end{tabular}
\end{table} | PMC2717465_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& & \textbf{Survivor (n = 52)} & \textbf{Non-survivor (n = 49)} & \textbf{P value} \\
\hline
\multirow{3}{*}{IL-6 (pg/ml)} & t0 & 104.5; 34.0 to 430.0 & 249.4; 96.5 to 460.2 & 0.099 \\
\hline
t48 & 21.0; 8.0 to 46.0 & 82.1; 37.4 to 188.5 & 0.001** \\
\hline
t120 & 17.2; 8.9 to 38.3 & 71.6; 15.7 to 107.1 & 0.01* \\
\hline
\textbf{P value} & t0-t48-t120 & < 0.001*** & 0.005** \\
\hline
\multirow{3}{*}{sICAM-1 (ng/ml)} & t0 & 447.5; 323.14 to 663.6 & 399.8; 327.9 to 655.4 & 0.841 \\
\hline
t48 & 434.1; 308.6 to 613.6 & 683.2; 348.3 to 1003.7 & 0.067 \\
\hline
t120 & 467.8; 320.4 to 593.0 & 630.2; 419.2 to 933.3 & 0.083 \\
\hline
\textbf{P value} & t0-t48-t120 & 0.432 & 0.829 \\
\hline
\multirow{3}{*}{sVCAM-1 (ng/ml)} & t0 & 1146.3; 911.3 to 1975.7 & 1227.5; 857.2 to 2242.5 & 0.837 \\
\hline
t48 & 882.0; 569.6 to 1236.1 & 1275.1; 1040.0 to 2799.2 & 0.027* \\
\hline
t120 & 748.5; 639.1 to 1202.6 & 1685.5; 958.7 to 2201.2 & 0.021* \\
\hline
\textbf{P value} & t0-t48-t120 & 0.097 & 0.505 \\
\hline
\multirow{3}{*}{Total CK-18 (U/l)} & t0 & 1581.9; 1030.0 to 2152.0 & 2006.5; 1169.9 to 4611.6 & 0.038* \\
\hline
t48 & 1579.5; 1359.8 to 2058.7 & 2007.1; 1239.0 to 4488.8 & 0.212 \\
\hline
t120 & 1829.6; 1581.9 to 2076.9 & 2533.0; 1675.2 to 3535.5 & 0.073 \\
\hline
\textbf{P value} & t0-t48-t120 & 0.396 & 0.814 \\
\hline
\multirow{3}{*}{CK-18 fragments (U/l)} & t0 & 357.7; 248.8 to 554.8 & 475.4; 301.5 to 1028.2 & 0.035* \\
\hline
t48 & 355.4; 229.0 to 455.46 & 603.6; 410.7 to 973.5 & 0.007** \\
\hline
t120 & 324.6; 283.7 to 499.9 & 508.5; 314.8 to 881.3 & 0.108 \\
\hline
\textbf{P value} & t0-t48-t120 & 0.717 & 0.939 \\
\hline
\multirow{3}{*}{Ratio} & t0 & 0.3; 0.16 to 0.33 & 0.2; 0.12 to 0.36 & 0.436 \\
\hline
t48 & 0.2; 0.15 to 0.30 & 0.3; 0.15 to 0.35 & 0.651 \\
\hline
t120 & 0.2; 0.15 to 0.27 & 0.3; 0.15 to 0.36 & 0.534 \\
\hline
\textbf{P value} & t0-t48-t120 & 0.405 & 0.939 \\
\hline
\end{tabular}
\end{table} | PMC2717465_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Parameter} & \textbf{Point estimate} & \textbf{Range} & \textbf{Source} \\
\hline
Candidemia risk and mortality \\
\hline
Risk of candidemia & 0.140 & 0.048 to 0.283 & See Table S1 in Additional data file 1 \\
\hline
Risk of CK/CG among candidemia & 0.148 & 0.132 to 0.361 & See Table S2 in Additional data file 1 \\
\hline
Candidemia attributable mortality & 0.4 & 0.2 to 0.8 & Golan and colleagues [22] \\
\hline
Mortality reduction with appropriate empiric therapy & 0.48 & 0.35 to 0.65 & Morrell and colleagues [12] (inverse) \\
\hline
Evaluation and treatment \\
\hline
Days of empiric treatment until availability of C&S results & 3 & 2 to 4 & Assumption \\
\hline
Total duration of appropriate treatment (days) & 10 & 7 to 14 & Guideline recommendations of 14 days reduced to 10 days to account for mortalities \\
\hline
Days of antibiotic treatment if switched from MIC to FLU in response to C&S & 7 & 4 to 10 & Total duration of appropriate treatment β Days of empiric treatment until availability of C&S results \\
\hline
Days of antibiotic treatment if switched from FLU to MIC in response to C&S & 10 & 7 to 14 & Total duration of appropriate treatment \\
\hline
Cost of antibiotics \\
\hline
MIC ($/100 mg daily IV) & $100 & $80 to 120 & WHC Pharmacy \\
\hline
FLU ($/400 mg daily IV) & $12 & $10 to 14 & WHC Pharmacy \\
\hline
FLU ($/400 mg single loading dose on day 1) & $12 & $10 to 14 & WHC Pharmacy \\
\hline
Life expectancy, QALY adjustment and lifetime costs \\
\hline
Median age (years) & 64 & 48 to 80 & Median from Table S1 in Additional data file 1; range is +/- 25\% median \\
\hline
Life expectancy (years) & 17.4 & 13.0 to 21.4 & Actuarial tables from the US Social Security Administration [24]; for men; range is +/-25\% \\
\hline
Relative risk of death & 0.51 & 0.49 to 0.59 & Quartin and colleagues [25] \\
\hline
QALY adjustment & 0.64 & 0.44 to 0.80 & Fowler and colleagues [26], and Davies and colleagues [27] \\
\hline
Age-specific annual healthcare costs/ survivor in 2001 $US* & $16,446 & $12,335 to $20,558 & Shorr and colleagues [29] \\
\hline
Annual discount rate & 3\% & 0 to 6\% & Weinstein and colleagues [19] \\
\hline
\end{tabular}
\end{table} | PMC2717466_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Outcome} & \textbf{Point estimate} & \textbf{95\% confidence interval*} \\
\hline
Empiric MIC compared with empiric FLU \\
\hline
Deaths averted & 4 & 2 to 13 \\
\hline
Incremental cost/death avertedβ & $61,446 & $43,821 to $80,039 \\
\hline
Incremental cost/life year savedβ ΒΆ & $22,230 & $18,201 to $26,088 \\
\hline
Incremental cost/QALYβ ΒΆ & $34,734 & $26,312 to $49,209 \\
\hline
Empiric MIC compared with watchful waiting strategy \\
\hline
Deaths averted & 29 & 11 to 69 \\
\hline
Incremental cost/death avertedβ & $9,892 & $3,771 to $26,065 \\
\hline
Incremental cost/life year savedβ ΒΆ & $17,777 & $14,174 to $21,360 \\
\hline
Incremental cost/QALYβ ΒΆ & $27,777 & $20,572 to $39,888 \\
\hline
Empiric FLU compared with watchful waiting strategy \\
\hline
Deaths averted & 25 & 9 to 57 \\
\hline
Incremental cost/death avertedβ & $1,704 & $640 to $4,839 \\
\hline
Incremental cost/life year savedβ ΒΆ & $17,070 & $13,582 to $20,436 \\
\hline
Incremental cost/QALYβ ΒΆ & $26,672 & $19,699 to $38,223 \\
\hline
\end{tabular}
\end{table} | PMC2717466_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{QALY conversion factor} & \multicolumn{6}{c|}{\textbf{Candidemia as percentage of all BSI}} \\
\hline
& \textbf{0.048} & \textbf{0.100} & \textbf{0.140} & \textbf{0.200} & \textbf{0.250} & \textbf{0.283} \\
\hline
0.44 & $50,722 & $50,609 & $50,522 & $50,391 & $50,282 & $50,210 \\
\hline
0.50 & $44,636 & $44,536 & $44,459 & $44,344 & $44,248 & $44,185 \\
\hline
0.55 & $40,578 & $40,487 & $40,417 & $40,313 & $40,226 & $40,168 \\
\hline
0.60 & $37,196 & $37,113 & $37,049 & $36,953 & $36,874 & $36,821 \\
\hline
0.64 & $34,872 & $34,794 & $34,734 & $34,644 & $34,569 & $34,520 \\
\hline
0.70 & $31,883 & $31,811 & $31,757 & $31,674 & $31,606 & $31,561 \\
\hline
0.75 & $29,757 & $29,691 & $26,639 & $29,563 & $29,499 & $29,457 \\
\hline
0.80 & $21,897 & $27,835 & $27,787 & $27,715 & $27,655 & $27,616 \\
\hline
\end{tabular}
\end{table} | PMC2717466_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
\textbf{Input} \\
\hline
Candidemia as \% BSI & 0.48 \\
\hline
CK/CG as \% candidemia & 0.132 \\
\hline
Candidemia attributable mortality & 0.2 \\
\hline
Candidemia mortality reduction if treated appropriately & 0.35 \\
\hline
Total duration of treatment with appropriate treatment (days) & 14 \\
\hline
Time to C&S results (days) & 4 \\
\hline
Time initial treatment following C&S results (days) & 10 \\
\hline
Time treatment following switch for C&S results (days) & 14 \\
\hline
Cost per day FLU ($) & $10 \\
\hline
Cost per extra 400 mg loading day 1 in FLU gr & $10 \\
\hline
Cost per day MIC ($) & $120 \\
\hline
Age & 80 \\
\hline
Life expectancy & 13 \\
\hline
Relative risk of death & 0.59 \\
\hline
Time-trade off utility (QALY adjustment) & 0.44 \\
\hline
Age-specific annual healthcare costs in 2001 $US* & $20,558 \\
\hline
Annual discount rate & 0\% \\
\hline
Outcome \\
\hline
Incremental lifetime cost per QALY & $72,318 \\
\hline
\end{tabular}
\end{table} | PMC2717466_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Parameter} & \textbf{All ICU patients} & \textbf{Sepsis} & \textbf{Non-sepsis} \\
\hline
Number & 170 & 122 & 48 \\
\hline
Sex (number male/number female) & 111/59 & 81/41 & 30/18 \\
\hline
Sex (\% male/female) & 65/35 & 66/34 & 62/38 \\
\hline
Age median (years; range) & 63 (18 to 86) & 64 (20 to 86) & 59.9 (18 to 79) \\
\hline
BMI median (range) & 25.8 (14 to 59.5) & 25.99 (14 to 59.5) & 25.1 (17.5 to 53.3) \\
\hline
Median days ICU (range) & 8.5 (1 to 137) & 10 (1 to 137) & 6 (1 to 45) \\
\hline
Median days hospital (range) & 27 (2 to 151) & 30 (2 to 151) & 14 (2 to 85) \\
\hline
Death ICU n (\%) & 54 (31.8) & 42 (34.4) & 12 (25) \\
\hline
Survival ICU n (\%) & 116 (68.2) & 80 (65.6) & 36 (75) \\
\hline
Death follow-up n (\%) & 88 (51.8) & 64 (52.5) & 24 (50) \\
\hline
Survival follow-up n (\%) & 82 (48.2) & 58 (47.5) & 24 (50) \\
\hline
Ventilation, n (yes/no) & 113/57 & 82/40 & 31/17 \\
\hline
Median ventilation time hours (range) & 66 (0 to 2966) & 127.5 (0 to 2966) & 31 (0 to 755) \\
\hline
Median CRP (mg/dl; range) & 90.5 (5 to 230) & 129.5 (5 to 230) & 14.5 (5 to 164) \\
\hline
Median creatinine (mg/dl; range) & 1.7 (0.1 to 14.1) & 1.9 (0.1 to 14.1) & 1.3 (0.3 to 13.1) \\
\hline
Median cystatin C (mg/l; range) & 1.83 (0.41 to 7.30) & 1.98 (0.41 to 6.33) & 1.34 (0.41 to 7.30) \\
\hline
Median lactate (nmol/l; range) & 1.7 (0.4 to 21.9) & 1.7 (0.4 to 21.9) & 2.1 (0.7 to 18.1) \\
\hline
Median APACHE II score (range) & 14 (0 to 31) & 14 (0 to 31) & 15 (0 to 31) \\
\hline
Median SAPS-2 score (range) & 44 (0 to 80) & 45 (0 to 79) & 41 (13 to 80) \\
\hline
\end{tabular}
\end{table} | PMC2717467_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Sepsis} & \textbf{Non-sepsis} \\
\hline
& n = 122 & n = 48 \\
\hline
Etiology of sepsis critical illness Site of infection n (\%) \\
\hline
Pulmonary & 72 (59\%) \\
\hline
Abdominal & 22 (18\%) \\
\hline
Other & 28 (23\%) \\
\hline
Etiology of non-sepsis critical illness n (\%) \\
\hline
Decompensated liver cirrhosis & & 17 (35\%) \\
\hline
Cardiopulmonary diseases & & 18 (38\%) \\
\hline
Other & & 13 (27\%) \\
\hline
\end{tabular}
\end{table} | PMC2717467_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multirow{2}{*}{\textbf{Controls n = 60}} & \multirow{2}{*}{\textbf{All ICU patients n = 170}} & \multirow{2}{*}{\textbf{Sepsis n = 122}} & \multirow{2}{*}{\textbf{Non-sepsis n = 48}} \\
\hline
\\
\hline
Resistin (ng/ml) median (range) & 4.7 (2.2 to 12.7) & 18 (3.22 to 50) & 24.2 (3.22 to 50) & 10.5 (3.33 to 41.1) \\
\hline
Resistin (ng/ml) 90\%-interval & 2.6 to 10.2 & 4.8 to 46.4 & 4.8 to 49.9 & 3.6 to 39.0 \\
\hline
\end{tabular}
\end{table} | PMC2717467_table_2 |
|
\begin{table}
\cente\textbf{\textbf{\textbf{r}}}ing
\label{tab:tablelabel}
\begin{tabula\textbf{\textbf{\textbf{r}}}}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{All patients}} & \multicolumn{2}{c|}{\textbf{Sepsis}} & \multicolumn{2}{c|}{\textbf{Non-sepsis}} \\
\hline
\textbf{\textbf{\textbf{\textbf{P}}}a\textbf{\textbf{\textbf{r}}}amete\textbf{\textbf{\textbf{r}}}s} & \textbf{\textbf{\textbf{r}}} & \textbf{\textbf{\textbf{P}}} & \textbf{\textbf{\textbf{r}}} & \textbf{\textbf{\textbf{P}}} & \textbf{\textbf{\textbf{r}}} & \textbf{\textbf{\textbf{P}}} \\
\hline
Ma\textbf{\textbf{\textbf{r}}}ke\textbf{\textbf{\textbf{r}}}s of inflammation \\
\hline
IL-6 & 0.477 & < 0.001 & 0.289 & 0.004 & 0.671 & < 0.001 \\
\hline
IL-10 & 0.273 & 0.002 & 0.231 & 0.027 & & ns \\
\hline
TNF-Ξ± & 0.509 & < 0.001 & 0.419 & < 0.001 & 0.687 & < 0.001 \\
\hline
CR\textbf{\textbf{\textbf{P}}} & 0.510 & < 0.001 & 0.395 & < 0.001 & 0.389 & 0.012 \\
\hline
\textbf{\textbf{\textbf{P}}}\textbf{\textbf{\textbf{r}}}ocalcitonin & 0.638 & < 0.001 & 0.594 & < 0.001 & 0.458 & 0.003 \\
\hline
Ma\textbf{\textbf{\textbf{r}}}ke\textbf{\textbf{\textbf{r}}}s of o\textbf{\textbf{\textbf{r}}}gan function \\
\hline
C\textbf{\textbf{\textbf{r}}}eatinine & 0.462 & < 0.001 & 0.420 & < 0.001 & 0.602 & < 0.001 \\
\hline
Cystatin C & 0.442 & < 0.001 & 0.404 & < 0.001 & & ns \\
\hline
Lactate & & ns & 0.286 & 0.006 & & ns \\
\hline
\textbf{\textbf{\textbf{P}}}CHE & -0.269 & 0.002 & -0.280 & 0.006 & & ns \\
\hline
Bili\textbf{\textbf{\textbf{r}}}ubin & 0.221 & 0.013 & 0.224 & 0.035 & & ns \\
\hline
Ma\textbf{\textbf{\textbf{r}}}ke\textbf{\textbf{\textbf{r}}}s of metabolism \\
\hline
\textbf{\textbf{\textbf{P}}}\textbf{\textbf{\textbf{r}}}otein & -0.199 & 0.02 & & ns & & ns \\
\hline
fT3 & -0.319 & < 0.001 & -0.252 & 0.016 & & ns \\
\hline
fT4 & -0.276 & 0.001 & -0.229 & 0.028 & & ns \\
\hline
Choleste\textbf{\textbf{\textbf{r}}}ol & -0.245 & 0.004 & -0.296 & 0.003 & & ns \\
\hline
HDL & -0.277 & 0.002 & -0.254 & 0.019 & & ns \\
\hline
LDL & -0.359 & < 0.001 & -0.378 & < 0.001 & & ns \\
\hline
Lp(a) & & ns & -0.223 & 0.040 & & ns \\
\hline
Glucose & -0.320 & < 0.001 & & ns & & ns \\
\hline
Insulin & -0.209 & 0.02 & & ns & & ns \\
\hline
HOMA IR & 0.314 & < 0.001 & & ns & & ns \\
\hline
\textbf{\textbf{\textbf{P}}}O4 & 0.321 & < 0.001 & 0.308 & 0.003 & 0.417 & 0.008 \\
\hline
Co\textbf{\textbf{\textbf{r}}}tisol & 0.312 & 0.001 & 0.275 & 0.010 & & ns \\
\hline
\textbf{\textbf{\textbf{P}}}a\textbf{\textbf{\textbf{r}}}atho\textbf{\textbf{\textbf{r}}}mone & 0.212 & 0.019 & 0.228 & 0.033 & & ns \\
\hline
Clinical sco\textbf{\textbf{\textbf{r}}}ing \\
\hline
A\textbf{\textbf{\textbf{P}}}ACHE II & & ns & & ns & 0.481 & 0.005 \\
\hline
\end{tabula\textbf{\textbf{\textbf{r}}}}
\end{table} | PMC2717467_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
Age, years, mean (SD) & 45.7 (9.5) \\
\hline
Years since medical school graduation, mean (SD) & 19.9 (9.7) \\
\hline
Decade of medical school graduation, number (\%) \\
\hline
1960s & 9 (3.1\%) \\
\hline
1970s & 65 (22.5\%) \\
\hline
1980s & 87 (30.1\%) \\
\hline
1990s & 104 (36.0\%) \\
\hline
2000s & 24 (8.3\%) \\
\hline
Primary employer, number (\%) \\
\hline
Private practice, community hospital, and/or managed care & 160 (55.6\%) \\
\hline
Academic medical center and/or University medical school & 108 (37.5\%) \\
\hline
Other & 20 (6.9\%) \\
\hline
Weight, pounds, mean (SD) & 173.6 (30.6) \\
\hline
Height, inches, mean (SD) & 68.7 (4.3) \\
\hline
BMI, kg/m2, mean (SD) & 26.0 (4.3) \\
\hline
Underweight BMI (<18.5 kg/m2), number (\%) & 2 (0.7\%) \\
\hline
Normal BMI (18.5 to 24.9 kg/m2), number (\%) & 126 (43.9\%) \\
\hline
Overweight BMI (25 to 29.9 kg/m2), number (\%) & 124 (43.2\%) \\
\hline
Obese BMI (=30 kg/m2), number (\%) & 35 (12.2\%) \\
\hline
Estimates of BMI of respondent's ICU patients, mean (SD) \\
\hline
Underweight BMI (<18.5 kg/m2) & 10.4\% (6.5) \\
\hline
Normal BMI (18.5 to 24.9 kg/m2) & 26.8\% (13.5) \\
\hline
Overweight BMI (25 to 29.9 kg/m2) & 30.6\% (11.7) \\
\hline
Obese BMI (30 to 39.9 kg/m2) & 22.8\% (11.7) \\
\hline
Severely obese BMI (=40 kg/m2) & 9.4\% (6.5) \\
\hline
Self-reported chronic health problem, number (\%) & 45 (16.2\%) \\
\hline
Percentage of job spent in direct care of ICU patients, mean (SD) & 38.8\% (22.2) \\
\hline
Number of septic patients cared for per week, number (\%) \\
\hline
0 & 3 (1.0\%) \\
\hline
1 to 2 & 62 (21.7\%) \\
\hline
3 to 5 & 115 (40.2\%) \\
\hline
6 to 10 & 71 (24.8\%) \\
\hline
11 to 15 & 24 (8.4\%) \\
\hline
15+ & 11 (3.8\%) \\
\hline
Self-rated experience treating sepsis, number (\%) \\
\hline
Limited & 1 (0.4\%) \\
\hline
Moderate & 109 (38.0\%) \\
\hline
Extensive & 177 (61.7\%) \\
\hline
Specialty, number (\%) \\
\hline
Internal medicine & 154 (54.0\%) \\
\hline
Family medicine & 1 (0.4\%) \\
\hline
Surgery & 3 (1.0\%) \\
\hline
Anesthesia & 3 (1.0\%) \\
\hline
Pulmonary & 267 (93.0\%) \\
\hline
Critical care & 262 (91.3\%) \\
\hline
Sleep medicine & 66 (23.0\%) \\
\hline
Other & 13 (4.5\%) \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\multicolumn{5}{c|}{\textbf{Vignette characteristics}} & \multicolumn{2}{c|}{\textbf{Predicted 'baseline' hospital mortality}} \\
\hline
\textbf{BMI} & \textbf{Age (years)} & \textbf{Co-morbidities} & \textbf{APACHE II Score} & \textbf{Number of vignettes} & \textbf{Median} & \textbf{5th percentile to 95th percentile range} \\
\hline
Normal & 50 & None & 25 & 285 & 37\% & 10\% to 69\% \\
\hline
Obese & 50 & None & 25 & 133 & 42\% & 16\% to 74\% \\
\hline
Normal & 50 & Early-stage lung cancer & 25 & 43 & 44\% & 21\% to 72\% \\
\hline
Normal & 70 & None & 25 & 123 & 46\% & 15\% to 74\% \\
\hline
Obese & 50 & Early-stage lung cancer & 25 & 42 & 49\% & 24\% to 80\% \\
\hline
Obese & 70 & None & 25 & 130 & 50\% & 28\% to 80\% \\
\hline
Normal & 70 & Early-stage lung cancer & 25 & 98 & 53.5\% & 20\% to 84\% \\
\hline
Obese & 70 & Early-stage lung cancer & 25 & 287 & 55\% & 27\% to 81\% \\
\hline
\multicolumn{4}{c|}{All vignettes} & 1141 & 47\% & 17\% to 78\% \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Univariable analyses}} & \multicolumn{2}{c|}{\textbf{Multivariable analyses}} \\
\hline
& \textbf{\textbf{Percentage point increase in predicted mortality (95\% confidence interval)}} & \textbf{\textbf{P value}} & \textbf{\textbf{Percentage point increase in predicted mortality (95\% confidence interval)}} & \textbf{\textbf{P value}} \\
\hline
70 years old (versus 50 years old) & 12.1 (10.0 to 14.2) & <0.0001 & 8.2 (6.1 to 10.4) & <0.0001 \\
\hline
Stage IIA NSCLC (versus no cancer) & 10.8 (8.7 to 13.0) & <0.0001 & 5.9 (3.6 to 8.1) & <0.0001 \\
\hline
BMI 40 kg/m2 (versus 22 kg/m2) & 8.6 (6.4 to 10.7) & <0.0001 & 4.3 (2.5 to 6.2) & <0.0001 \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\multicolumn{5}{c|}{\textbf{Vignette characteristics}} & \multicolumn{2}{c|}{\textbf{Predicted problems washing and dressing self at six months (assuming survival)}} \\
\hline
\textbf{BMI} & \textbf{Age (years)} & \textbf{Co-morbidities} & \textbf{APACHE II Score} & \textbf{Number of vignettes} & \textbf{Median} & \textbf{5th percentile to 95th percentile range} \\
\hline
Normal & 50 & None & 25 & 285 & 12\% & 1\% to 58\% \\
\hline
Obese & 50 & None & 25 & 133 & 20\% & 3\% to 66\% \\
\hline
Normal & 50 & Early-stage lung cancer & 25 & 43 & 25\% & 3\% to 55\% \\
\hline
Normal & 70 & None & 25 & 124 & 25\% & 4\% to 69\% \\
\hline
Obese & 50 & Early-stage lung cancer & 25 & 42 & 28.5\% & 2\% to 70\% \\
\hline
Obese & 70 & None & 25 & 130 & 32\% & 4\% to 74\% \\
\hline
Normal & 70 & Early-stage lung cancer & 25 & 98 & 31.5\% & 4\% to 77\% \\
\hline
Obese & 70 & Early-stage lung cancer & 25 & 287 & 39\% & 8\% to 81\% \\
\hline
All vignettes & & & & 1142 & 25\% & 2\% to 74\% \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Univariable analyses}} \\
\hline
& \textbf{Percentage point increase in predicted problems with self-care in six months (95\% confidence interval)} & \textbf{P value} \\
\hline
70 years old (versus 50 years old) & 16.1 (14.0 to 18.1) & <0.0001 \\
\hline
Stage IIA NSCLC (versus no cancer) & 13.5 (11.3 to 15.7) & <0.0001 \\
\hline
BMI 40 kg/m2 (versus 22 kg/m2) & 10.9 (9.2 to 12.6) & <0.0001 \\
\hline
Respondent age (per decade of age) & -4.5 (-6.5 to -2.5) & <0.0001 \\
\hline
Respondent self-reported chronic health condition & -7.3 (-11.8 to -2.8) & 0.0016 \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Multivariable analysis}} & \multicolumn{2}{c|}{\textbf{Multivariable analysis}, including respondent factors} \\
\hline
& \textbf{Percentage point increase in predicted problems with self-care in six months (95\% confidence interval)} & \textbf{\textbf{P value}} & \textbf{Percentage point change in predicted problems with self-care in six months (95\% confidence interval)} & \textbf{\textbf{P value}} \\
\hline
70 years old (versus 50 years old) & 11.5 (9.0 to 13.9) & <0.0001 & 11.6 (9.2 to 13.9) & <0.0001 \\
\hline
Stage IIA NSCLC (versus no cancer) & 6.8 (4.3 to 9.3) & <0.0001 & 6.9 (4.3 to 9.4) & <0.0001 \\
\hline
BMI 40 kg/m2 (versus 22 kg/m2) & 5.4 (3.3 to 7.5) & <0.0001 & 5.3 (3.2 to 7.4) & <0.0001 \\
\hline
Respondent age (per decade of age) & & & -4.0 (-6.0 to -2.0) & 0.0001 \\
\hline
Respondent self-reported chronic health condition & & & -5.8 (-10.1 to -1.4) & 0.0103 \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_5 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
& \multicolumn{2}{c|}{\textbf{Univariable analyses}} \\
\hline
& \textbf{Odds ratio (95\% CI)} & \textbf{P value} \\
\hline
70 years old (versus 50 years old) & 6.76 (3.96 to 11.55) & <0.0001 \\
\hline
Stage IIA NSCLC (versus no cancer) & 10.95 (6.30 to 19.03) & <0.0001 \\
\hline
BMI 40 kg/m2 (versus 22 kg/m2) & 2.54 (1.78 to 3.62) & <0.0001 \\
\hline
Baseline predicted hospital mortality (per 10\% increase) & 1.63 (1.41 to 1.89) & <0.0001 \\
\hline
Predicted problems with self-care at six months (per 10\% increase) & 1.46 (1.32 to 1.62) & <0.0001 \\
\hline
Overweight or obese respondent BMI & 0.55 (0.33 to 0.93) & 0.0258 \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_6 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{6}{c|}{\textbf{Multivariable analyses}} \\
\hline
& \textbf{\textbf{\textbf{Adjusted odds ratio (95\% CI)}}} & \textbf{\textbf{\textbf{P value}}} & \textbf{\textbf{\textbf{Adjusted odds ratio (95\% CI)}}} & \textbf{\textbf{\textbf{P value}}} & \textbf{\textbf{\textbf{Adjusted odds ratio (95\% CI)}}} & \textbf{\textbf{\textbf{P value}}} \\
\hline
70 years old (versus 50 years old) & 2.90 (1.55 β 5.44) & 0.0009 & 1.90 (0.98 to 3.68) & 0.0589 & 1.87 (0.95 to 3.66) & 0.0685 \\
\hline
Stage IIA NSCLC (versus no cancer) & 7.12 (3.75 β 13.52) & <0.0001 & 5.70 (2.97 to 10.93) & <0.0001 & 5.84 (3.05 to 11.20) & <0.0001 \\
\hline
BMI 40 kg/m2 (versus 22 kg/m2) & 1.18 (0.78 β 1.79) & 0.4274 & 1.02 (0.66 to 1.57) & 0.9375 & 1.01 (0.65 to 1.56) & 0.9694 \\
\hline
Baseline predicted hospital mortality (per 10\% increase) & & & 1.30 (1.10 to 1.54) & 0.0019 & 1.29 (1.09 to 1.53) & 0.0027 \\
\hline
Predicted problems with self-care at six months (per 10\% increase) & & & 1.26 (1.12 to 1.41) & <0.0001 & 1.26 (1.12 to 1.42) & 0.0002 \\
\hline
Overweight or obese respondent BMI & & & & & 0.53 (0.29 to 0.96) & 0.0345 \\
\hline
\end{tabular}
\end{table} | PMC2717468_table_7 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Successful weaning group (n = 16)} & \textbf{Failed weaning group (n = 14)} & \textbf{P value} \\
\hline
Gender, male/female & 9/7 & 10/4 & NS \\
\hline
Age, years & 67.6 $\pm$ 13.5 & 70.9 $\pm$ 11 & NS \\
\hline
Body mass index & 24 $\pm$ 5.6 & 21.6 $\pm$ 2.6 & NS \\
\hline
SAPS II & 29.6 $\pm$ 7.3 & 31.6 $\pm$ 6 & NS \\
\hline
Diagnosis & & & NS \\
\hline
Post-cardiac surgery & 5 & 4 \\
\hline
ALI/ARDS & 5 & 2 \\
\hline
COPD exacerbation & 6 & 8 \\
\hline
Duration of MV at the time of the studya & 37.5 $\pm$ 19.6 (25β40) & 48.9 $\pm$ 26.9 (30β60) & NS \\
\hline
\end{tabular}
\end{table} | PMC2717469_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Successful weaning group (n = 16)} & \textbf{Failed weaning group (n = 14)} & \textbf{P value} \\
\hline
Ventilatory pattern \\
\hline
VT, mL & 336.5 $\pm$ 158.3 & 299.5 $\pm$ 213.4 & NS \\
\hline
f, breaths/min & 26.1 $\pm$ 7.5 & 32.4 $\pm$ 5.2 & 0.01 \\
\hline
f/VT & 109.4 $\pm$ 74.5 & 173.9 $\pm$ 103.4 & NS \\
\hline
Respiratory mechanics \\
\hline
CLdyn, L/cm H2O & 0.049 $\pm$ 0.032 & 0.051 $\pm$ 0.035 & NS \\
\hline
RL, cm H2O/L per s & 13.4 $\pm$ 9.0 & 12.9 $\pm$ 9.4 & NS \\
\hline
PEEPi,dyn, cm H2O & 1.93 $\pm$ 1.36 & 2.7 $\pm$ 3.1 & NS \\
\hline
Inspiratory muscle function \\
\hline
MIP, cm H2O & 45.2 $\pm$ 19.5 & 32.7 $\pm$ 18.2 & NS \\
\hline
Pdimax, cm H2O & 34.9 $\pm$ 18.9 & 25.4 $\pm$ 17.3 & NS \\
\hline
Pdisw/Pdimax, percentage & 36.1 $\pm$ 15.8 & 54.4 $\pm$ 25.5 & 0.02 \\
\hline
PTPdi/min, cm H2O/s & 235.8 $\pm$ 126.9 & 268.0 $\pm$ 234.8 & NS \\
\hline
TTdi & 0.13 $\pm$ 0.065 & 0.21 $\pm$ 0.12 & 0.02 \\
\hline
\end{tabular}
\end{table} | PMC2717469_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Successful weaning group (n = 16)} & \textbf{Failed weaning group (n = 14)} & \textbf{P value} \\
\hline
Ventilatory pattern \\
\hline
VT, mL & 385.8 $\pm$ 132.2 & 289.3 $\pm$ 138.4 & NS \\
\hline
f, breaths/min & 22.6 $\pm$ 6.0 & 27.4 $\pm$ 7.3 & NS \\
\hline
f/VT & 74.1 $\pm$ 44.0 & 148.2 $\pm$ 121.4 & 0.03 \\
\hline
Respiratory mechanics \\
\hline
CLdyn, L/cm H2O & 0.067 $\pm$ 0.033 & 0.049 $\pm$ 0.024 & NS \\
\hline
RL, cm H2O/L per s & 8.8 $\pm$ 5.8 & 14.4 $\pm$ 14.2 & NS \\
\hline
PEEPi,dyn, cm H2O & 1.5 $\pm$ 1.0 & 1.7 $\pm$ 1.66 & NS \\
\hline
Inspiratory muscle function \\
\hline
MIP, cm H2O & 57.3 $\pm$ 18.2 & 38.6 $\pm$ 13.5 & 0.001 \\
\hline
Pdimax, cm H2O & 43.0 $\pm$ 20.0 & 27.7 $\pm$ 12.5 & 0.01 \\
\hline
Pdisw/Pdimax, percentage & 23.1 $\pm$ 7.9 & 42.5 $\pm$ 22.9 & 0.003 \\
\hline
PTPdi/min, cm H2O/s & 194.1 $\pm$ 84.8 & 216.2 $\pm$ 136.8 & NS \\
\hline
TTdi & 0.08 $\pm$ 0.029 & 0.14 $\pm$ 0.054 & 0.009 \\
\hline
\end{tabular}
\end{table} | PMC2717469_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Group} & \textbf{MIP, cm H2O} & \textbf{Pdimax, cm H2O} & \textbf{Pdisw/Pdimax, percentage} & \textbf{TTdi} \\
\hline
Successful weaning \\
\hline
T0 & 45.2 $\pm$ 19.5 & 34.9 $\pm$ 18.9a & 36.0 $\pm$ 15.8a & 0.13 $\pm$ 0.065b \\
\hline
T1 & 57.3 $\pm$ 18.2b & 43.0 $\pm$ 20.04a & 23.1 $\pm$ 7.9a,b & 0.08 $\pm$ 0.029 \\
\hline
Failed weaning \\
\hline
T0 & 32.7 $\pm$ 18.2 & 25.4 $\pm$ 17.3 & 54.4 $\pm$ 25.5 & 0.21 $\pm$ 0.122a,b \\
\hline
T1 & 38.6 $\pm$ 13.5b & 27.7 $\pm$ 12.5 & 42.5 $\pm$ 22.9b & 0.14 $\pm$ 0.054a \\
\hline
\end{tabular}
\end{table} | PMC2717469_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Group} & \textbf{T0} & \textbf{T1} \\
\hline
Successful weaning \\
\hline
COPD & 50.2 $\pm$ 11.9 (4.9) & 59.3 $\pm$ 13.5 (5.5)a \\
\hline
Non-COPD & 28.83 $\pm$ 16.5 (5.2) & 33.2 $\pm$ 16.9 \\
\hline
Failed weaning \\
\hline
COPD & 32.1 $\pm$ 17.6 (6.2) & 32.1 $\pm$ 10.6 (3.7)a \\
\hline
Non-COPD & 16.5 $\pm$ 13.5a (5.5) & 22 $\pm$ 13.5 (5.5)a \\
\hline
\end{tabular}
\end{table} | PMC2717469_table_4 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Group} & \textbf{Parameter} & \textbf{Baseline} & \textbf{Day 1 post I/R} & \textbf{Day 3 post I/R} \\
\hline
Vasopressin n = 14 & HR (bpm): LVEDV (uL): & 495 $\pm$ 18.1 67 $\pm$ 5 & 517.15 $\pm$ 15.67 58 $\pm$ 8 & 485.11 $\pm$ 34.94 60 $\pm$ 9 \\
\hline
Dobutamine n = 6 & HR (bpm): LVEDV (uL): & 439 $\pm$ 28.7 64 $\pm$ 7 & 475.17 $\pm$ 32.35 55 $\pm$ 7 & 507.1 $\pm$ 50.68 55 $\pm$ 7 \\
\hline
Normal Saline n = 9 & HR (bpm): LVEDV (uL): & 448 $\pm$ 15.1 69 $\pm$ 4 & 486.66 $\pm$ 16.29 60 $\pm$ 6 & 438 $\pm$ 32.10 58 $\pm$ 6 \\
\hline
\end{tabular}
\end{table} | PMC2717470_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Study days} & \textbf{0a} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} \\
\hline
& First suction blister induction & & & & Second suction blister induction \\
\hline
& \multicolumn{\textbf{5}}{c|}{Early wound} \\
\hline
& & & & & \multicolumn{\textbf{5}}{c|}{Late wound} \\
\hline
Measurements & Blood flow and water evaporation & & & & Blood flow and water evaporation (from both wounds) & & & & Blood flow and water evaporation \\
\hline
\end{tabular}
\end{table} | PMC2717472_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|}
\hline
& \textbf{Septic patients} \\
\hline
Male gender & 22 (63\%) \\
\hline
Age, years & 62 (range 24 to 80, SD 12) \\
\hline
Body mass index, kg/m2 & 28 (range 21 to 47, SD 6) \\
\hline
Co-morbidities \\
\hline
Diabetes mellitus & 9 (26\%) \\
\hline
COPD & 4 (11\%) \\
\hline
Asthma & 3 (9\%) \\
\hline
Ischaemic heart disease & 7 (20\%) \\
\hline
Focus of infection \\
\hline
Lungs & 15 (43\%) \\
\hline
Intra-abdominal & 12 (34\%) \\
\hline
Urinary & 1 (3\%) \\
\hline
Primary blood & 2 (6\%) \\
\hline
Other & 5 (14\%) \\
\hline
Severity of the disease \\
\hline
APACHE II score on admission & 25 (range 9 to 44, SD 8) \\
\hline
SOFA score & 9.3 (range 1 to 22, SD 4) \\
\hline
Sepsis steroid & 24 (69\%) \\
\hline
Septic shock & 29 (83\%) \\
\hline
Multiple organ failure & 23 (66\%) \\
\hline
Outcome variables \\
\hline
ICU length of stay, days & 7.9 (range 2 to 30, SD 6) \\
\hline
ICU mortality & 7 (20\%) \\
\hline
Hospital mortality & 9 (26\%) \\
\hline
30-day mortality & 10 (29\%) \\
\hline
\end{tabular}
\end{table} | PMC2717472_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Group} & \multicolumn{2}{c|}{\textbf{Day 0 of the early wound}} & \multicolumn{2}{c|}{\textbf{Day 4 of the early wound}} & \multicolumn{2}{c|}{\textbf{Day 0 of the late wound}} & \multicolumn{2}{c|}{\textbf{Day 4 of the late wound}} \\
\hline
& \textbf{\textbf{\textbf{\textbf{TEWL}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{TEWL}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{TEWL}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{TEWL}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} \\
\hline
Septic & 168 & 58 & 102 & 93 & 180 & 88 & 86 & 45 \\
\hline
\multirow{2}{*}{Controls} & 195 & 30 & 73 & 31 & 195 & 30 & 73 & 31 \\
\hline
\multicolumn{2}{c|}{P = 0.087} & \multicolumn{2}{c|}{P = 0.484} & \multicolumn{2}{c|}{P = 0.424} & \multicolumn{2}{c|}{P = 0.590} \\
\hline
\end{tabular}
\end{table} | PMC2717472_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Group} & \multicolumn{2}{c|}{\textbf{Day 0 of the early wound}} & \multicolumn{2}{c|}{\textbf{Day 4 of the early wound}} & \multicolumn{2}{c|}{\textbf{Day 0 of the late wound}} & \multicolumn{2}{c|}{\textbf{Day 4 of the late wound}} \\
\hline
& \textbf{\textbf{\textbf{\textbf{BF}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{BF}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{BF}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} & \textbf{\textbf{\textbf{\textbf{BF}}}} & \textbf{\textbf{\textbf{\textbf{SD}}}} \\
\hline
Septic & 76 & 49 & 110 & 67 & 101 & 50 & 110 & 58 \\
\hline
\multirow{2}{*}{Controls} & 51 & 11 & 47 & 24 & 51 & 11 & 47 & 24 \\
\hline
\multicolumn{2}{c|}{P = 0.273} & \multicolumn{2}{c|}{P = 0.001} & \multicolumn{2}{c|}{P = 0.001} & \multicolumn{2}{c|}{P = 0.005} \\
\hline
\end{tabular}
\end{table} | PMC2717472_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \textbf{Purulent meningitis of known aetiology (n = 31)} & \textbf{Purulent meningitis of unknown aetiology (n = 20)} & \textbf{Lymphocytic meningitis (n = 59)} & \textbf{Encephalitis (n = 11)} & \textbf{No CNS infection (n = 50)} \\
\hline
Female sex & 45\% (14/31) & 50\% (10/20) & 41\% (24/59) & 45\% (5/11) & 48\% (24/50) \\
\hline
Age (in years) & 20 (10β53) (31/31) & 23 (7β30) (20/20) & 25 (17β31)β‘ (59/59) & 55 (46β64) (11/11) & 28 (10β44) (50/50) \\
\hline
Underlying illness* & 23\%β (7/31) & 10\% (2/20) & 2\% (1/59) & 0\% (0/11) & 4\% (2/50) \\
\hline
Body temperature (Β°C) & 38.8 (38.4β39.6)β (27/31) & 38.3 (38.0β39.2) (18/20) & 38.1 (37.7β38.7) (49/59) & 37.8 (37.1β38.9) (9/11) & 39 (37.5β39.6) (37/50) \\
\hline
Mean arterial pressure (mmHg) & 93 (87β117) (22/31) & 90 (79β106) (12/20) & 90 (82β100) (42/59) & 102 (86β115) (10/11) & 93 (77β103) (30/50) \\
\hline
Heart rate (beats/minute) & 113 (98β129)β β‘ (20/31) & 90 (80β108) (16/20) & 88 (73β100) (44/59) & 80 (70β101) (10/11) & 100 (85β120) (30/50) \\
\hline
Septic shock & 16\%β (5/31) & 0\% (0/20) & 0\% (0/59) & 0\% (0/11) & 8\% (4/50) \\
\hline
Back rigidity & 80\%* (24/30) & 95\%β‘Β§ (18/19) & 88\%β‘Β§ (51/58) & 40\% (4/10) & 57\% (26/46) \\
\hline
Decreased consciousness & 66\%*β Β§ (19/29) & 22\%β β‘ (4/18) & 0\%β‘ (0/57) & 91\%Β§ (10/11) & 13\% (6/46) \\
\hline
Assisted ventilation & 45\%*β Β§ (14/31) & 0\% (0/20) & 0\% (0/59) & 20\% (2/10) & 10\% (5/50) \\
\hline
Steroid therapy & 35\%*β Β§ (11/31) & 0\% (0/20) & 0\% (0/59) & 10\% (1/10) & 0\% (0/50) \\
\hline
Fatal outcome & 23\%β (7/31) & 5\% (1/20) & 0\% (0/59) & 18\% (2/11) & 4\% (2/50) \\
\hline
Days in hospital (survivors) & 11 (9β15)β Β§ (24/24) & 9 (8β12)β Β§ (19/19) & 4 (2β5)β‘ (59/59) & 12 (11β30)Β§ (9/9) & 4 (2β7) (48/48) \\
\hline
CSF WBC count (Γ 106 cells/l) & 3380 (767β6,528)*β β‘Β§ (31/31) & 359 (128β1,066)β‘Β§ (20/20) & 139 (61β366)Β§ (59/59) & 57 (13β102)Β§ (11/11) & 1 (1β2) (50/50) \\
\hline
CSF PMNs (Γ 106 cells/l) & 2,727 (398β5,404)*β β‘Β§ (30/31) & 305 (112β600)β β‘Β§ (20/20) & 25 (7β75)Β§ (56/59) & 5 (2β29)Β§ (9/11) & < 1 \\
\hline
CSF mononuclear (Γ 106 cells/l) & 248 (38β523)Β§ 30/31 & 16 (6β93)Β§ (20/20) & 74 (25β327)Β§ (56/59) & 79 (25β106)Β§ (9/11) & < 1 \\
\hline
CSF glucose (mmol/l) & 2.2 (0.6β3.5)β Β§ (30/31) & 3.3 (3.0β3.7)Β§ (17/20) & 3.3 (3.0β3.6)Β§ (56/59) & 3.1 (2.7β3.9) (10/11) & 3.7 (3.4β4.5) (48/50) \\
\hline
CSF/blood glucose ratio & 0.3 (0.1β0.5)*β Β§ (22/31) & 0.6 (0.4β0.7) (15/20) & 0.6 (0.5β0.7) (46/59) & 0.5 (0.3β0.7) (8/11) & 0.6 (0.6β0.8) (30/50) \\
\hline
CSF protein (g/l) & 1.9 (1.5β4.8)*β Β§ (30/31) & 0.7 (0.7β1.4)Β§ (20/20) & 0.7 (0.4β1.3)Β§ (54/59) & 1.1 (0.6β1.7)Β§ (11/11) & 0.3 (0.2β0.5) (47/50) \\
\hline
Blood WBC count (Γ 109 cells/l) & 21.7 (14.1β24.4)β β‘Β§ (31/31) & 14.4 (8.3β16.8)β (20/20) & 8.8 (7.3β10.9) (59/59) & 7.4 (6.9β9.6) (9/11) & 9.0 (6.2β12.8) (48/50) \\
\hline
Blood PMNs (Γ 109 cells/L) & 17.1 (12.5β21.5)*β β‘Β§ (30/31) & 10.9 (7.0β15.0)β Β§ (20/20) & 6.8 (5.3β8.5) (58/59) & 4.5 (4.1β9.2) (4/11) & 6.0 (4.5β9.6) (39/50) \\
\hline
Blood lymphocytes (Γ 109 cells/L) & 1.1 (0.7β1.5) (30/31) & 1.4 (1.1β1.8) (20/20) & 1.5 (1.0β1.9) (58/59) & 1.7 (0.8β2.1) (4/11) & 1.3 (0.8β2.1) (38/50) \\
\hline
Blood monocytes (Γ 109 cells/l) & 0.7 (0.4β1.0)β (30/31) & 0.6 (0.4β0.9) (20/20) & 0.4 (0.3β0.6) (58/59) & 0.6 (0.3β0.9) (4/11) & 0.4 (0.3β0.8) (38/50) \\
\hline
Platelets (Γ 109 cells/l) & 235 (166β286) (31/31) & 286 (215β370) (20/20) & 254 (210β310) (56/59) & 231 (174β351) (9/11) & 230 (168β275) (47/50) \\
\hline
Sodium (mmol/l) & 136 (135β138) (30/31) & 136 (133β139) (20/20) & 138 (136β140) (59/59) & 130 (127β140) (8/11) & 138 (136β141) (43/50) \\
\hline
Potassium (mmol/l) & 3.6 (3.3β3.9)β (29/31) & 3.8 (3.6β4.1) (19/20) & 3.9 (3.7β4.2) (59/59) & 4.0 (3.9β4.1) (7/11) & 3.9 (3.4β4.3) (44/50) \\
\hline
(ΞΌmol/l) Creatinine & 76 (54β85) (30/31) & 58 (46/72) (18/20) & 75 (55β85) (56/59) & 83 (73β100) (7/11) & 71 (49β87) (45/50) \\
\hline
Factors II, IIV and X & 0.57 (0.4β0.7)β (28/31) & 0.92 (0.7β1.0) (11/20) & 0.78 (0.7β1.0) (36/59) & 0.73 (0.6β1.0) (7/11) & 0.74 (0.5β0.9) (31/50) \\
\hline
Arterial PO2 (kPa) & 11.0 (9.0β13.0) (15/31) & 12.3 (10.7β13.8) (7/20) & 8.5 (7.8β11.5) (3/59) & 5.2 (1/11) & 12.7 (8.0β15.0) (6/50) \\
\hline
Positive blood culture & 62\%*β β‘Β§ (18/29) & 0\% (0/20) & 0\% (0/59) & 0\% (0/10) & 6\% (3/48) \\
\hline
\end{tabular}
\end{table} | PMC2717473_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{CSF samples} & \textbf{Purulent meningitis of known aetiology (n = 31)} & \textbf{Purulent meningitis of unknown aetiology (n = 20)} & \textbf{Lymphocytic meningitis (n = 59)} & \textbf{Encephalitis (n = 11)} & \textbf{No CNS infection (n = 50)} \\
\hline
CSF WBC count & 0.49β & -0.21 & 0.35β & 0.61* & 0.07 \\
\hline
CSF PMNs & 0.50β & -0.20 & -0.04 & 0.88β & -0.24 \\
\hline
CSF mononuclear & 0.39* & -0.44 & 0.37β & 0.18 & 0.13 \\
\hline
CSF glucose & -0.55β‘ & 0.17 & -0.04 & -0.25 & 0.14 \\
\hline
CSF/blood glucose & -0.51* & -0.22 & 0.12 & -0.21 & -0.16 \\
\hline
CSF protein & 0.42* & 0.12 & 0.31* & 0.36 & 0.39β \\
\hline
CSF lactoferrin & 0.45* & -0.33 & 0.15 & 0.95* & 0.20 \\
\hline
CSF neopterin & 0.32 & -0.14 & 0.33* & 0.80 & 0.17 \\
\hline
Blood WBC count & 0.13 & -0.19 & -0.18 & -0.50 & 0.06 \\
\hline
Blood neutrophils & 0.22 & -0.14 & -0.18 & -0.40 & -0.04 \\
\hline
Blood lymphocytes & -0.27 & -0.29 & 0.04 & -0.40 & 0.02 \\
\hline
Blood monocytes & 0.18 & -0.60* & -0.14 & -0.40 & 0.11 \\
\hline
\end{tabular}
\end{table} | PMC2717473_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \textbf{All} & \textbf{Thoracic} & \textbf{Abdominal} & \textbf{Obesity} & \textbf{Hepatic} & \textbf{Urological} & \textbf{Other} \\
\hline
N. of patients & 102 & 27 & 27 & 20 & 11 & 7 & 10 \\
\hline
Age (years) & 62 $\pm$ 17 & 67 $\pm$ 8 & 69 $\pm$ 17 & 40 $\pm$ 9 & 58 $\pm$ 18 & 64 $\pm$ 14 & 69 $\pm$ 17 \\
\hline
Surgery (min) & 178 $\pm$ 95 & 166 $\pm$ 64 & 200 $\pm$ 111 & 121 $\pm$ 38 & 267 $\pm$ 106 & 297 $\pm$ 80 & 146 $\pm$ 103 \\
\hline
Unscheduled (n) & 5 & - & 2 & - & - & - & 3 \\
\hline
APACHE II score & 8.4 $\pm$ 4 & 9.1 $\pm$ 3 & 9.7 $\pm$ 4 & 4.7 $\pm$ 2 & 8.4 $\pm$ 5 & 9.0 $\pm$ 3 & 9.3 $\pm$ 4 \\
\hline
EA activity & 0,3 $\pm$ 0.3 & 0.4 $\pm$ 0.2 & 0.3 $\pm$ 0.2 & 0.4 $\pm$ 0.2 & 0.3 $\pm$ 0.3 & 0.3 $\pm$ 0.3 & 0.4 $\pm$ 0.1 \\
\hline
LOS ICU (days) & 1 (1 to 2) & 1 (1 to 2) & 1 (1 to 4.7) & 1 (1 to 1) & 1 (1 to 1) & 1 (1 to 1) & 1 (1 to 2) \\
\hline
Mortality ICU (n) & 3 & - & 2 & - & - & - & - \\
\hline
LOS hosp (days) & 8 (5β11) & 8.5 (6β13) & 10 (7β16) & 4 (4β5) & 8.0 (6β10) & 12 (9β13) & 6.5 (5β10) \\
\hline
Mortality hosp (n) & 1 & 1 & - & - & - & - & - \\
\hline
\end{tabular}
\end{table} | PMC2717474_table_0 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
& & \textbf{Low} & \textbf{Intermediate} & \textbf{High} \\
\hline
\multirow{2}{*}{Ventilated patients} & Admission & 62/68 (91\%) & 16/17 (94\%) & 17/17 (100\%) \\
\hline
Day 1 & 6/68 (9\%)* & 1/17 (6\%)* & 1/17 (6\%)* \\
\hline
\multirow{2}{*}{Tidal volume (l/min)} & Admission & 6.5 $\pm$ 1.8 & 6.4 $\pm$ 1.2 & 7.3 $\pm$ 1.9 \\
\hline
Day 1 & / & / & / \\
\hline
\multirow{2}{*}{Respiratory rate (atti/minuto)} & Admission & 11 $\pm$ 4 & 11 $\pm$ 2 & 12 $\pm$ 7 \\
\hline
Day 1 & 18 $\pm$ 5* & 19 $\pm$ 5* & 16 $\pm$ 4* \\
\hline
\multirow{2}{*}{PaO2/FiO2 (mmHg)} & Admission & 379 $\pm$ 111 & 413 $\pm$ 113 & 372 $\pm$ 96 \\
\hline
Day 1 & 329 $\pm$ 62* & 330 $\pm$ 46* & 299 $\pm$ 83* \\
\hline
\multirow{2}{*}{PaCO2 (mmHg)} & Admission & 38.6 $\pm$ 4.9 & 35.1 $\pm$ 5.6# & 37.7 $\pm$ 5.0 \\
\hline
Day 1 & 39.9 $\pm$ 4.7 & 39.3 $\pm$ 5.1* & 38.8 $\pm$ 4.1 \\
\hline
\multirow{2}{*}{pH arterial blood} & Admission & 7.41 $\pm$ 0.05 & 7.42 $\pm$ 0.06 & 7.39 $\pm$ 0.06 \\
\hline
Day 1 & 7.43 $\pm$ 0.03 & 7.43 $\pm$ 0.03 & 7.43 $\pm$ 0.04 \\
\hline
\multirow{2}{*}{Lactate (mmol/l)} & Admission & 1.12 $\pm$ 0.57 & 1.23 $\pm$ 0.47 & 1.40 $\pm$ 1.39 \\
\hline
Day 1 & 0.79 $\pm$ 0.38* & 0.81 $\pm$ 0.37* & 0.89 $\pm$ 0.57 \\
\hline
\multirow{2}{*}{Heart rate (bpm)} & Admission & 76 $\pm$ 16 & 75 $\pm$ 17 & 77 $\pm$ 18 \\
\hline
Day 1 & 82 $\pm$ 15* & 80 $\pm$ 12 & 84 $\pm$ 15 \\
\hline
\multirow{2}{*}{Mean arterial pressure (mmHg)} & Admission & 88 $\pm$ 13 & 87 $\pm$ 13 & 92 $\pm$ 17 \\
\hline
Day 1 & 91 $\pm$ 12 & 94 $\pm$ 13 & 93 $\pm$ 16 \\
\hline
\multirow{2}{*}{Central venous pressure (mmHg)} & Admission & 7.5 $\pm$ 2.5 & 6.3 $\pm$ 2.9 & 7.5 $\pm$ 2.2 \\
\hline
Day 1 & 6.1 $\pm$ 2.6 & 6.1 $\pm$ 2.5 & 6.1 $\pm$ 2.7 \\
\hline
\multirow{2}{*}{Hemoglobin (g/dl)} & Admission & 12.0 $\pm$ 3.5 & 12.4 $\pm$ 1.8 & 12.4 $\pm$ 1.6 \\
\hline
Day 1 & 11.3 $\pm$ 1.6 & 11.5 $\pm$ 1.7 & 12.0 $\pm$ 1.3 \\
\hline
\multirow{2}{*}{Creatinine (mg/dl)} & Admission & 0.99 $\pm$ 0.92 & 1.06 $\pm$ 0.68 & 0.89 $\pm$ 0.37 \\
\hline
Day 1 & 1.04 $\pm$ 1.12 & 1.05 $\pm$ 0.47 & 0.85 $\pm$ 0.27 \\
\hline
\multirow{2}{*}{Azotemia (mg/dl)} & Admission & 36 $\pm$ 24 & 40 $\pm$ 21 & 37 $\pm$ 21 \\
\hline
Day 1 & 37 $\pm$ 27 & 41 $\pm$ 24 & 36 $\pm$ 25 \\
\hline
\multirow{2}{*}{Glycemia (mg/dl)} & Admission & 134 $\pm$ 30 & 134 $\pm$ 25 & 132 $\pm$ 35 \\
\hline
Day 1 & 110 $\pm$ 29* & 111 $\pm$ 23* & 105 $\pm$ 21* \\
\hline
\multirow{2}{*}{Sodium (Na+; mEq/l)} & Admission & 137.5 $\pm$ 2.5 & 137.1 $\pm$ 2.2 & 137.8 $\pm$ 2.1 \\
\hline
Day 1 & 137.9 $\pm$ 2.7 & 138.4 $\pm$ 3.5 & 138.1 $\pm$ 2.7 \\
\hline
\multirow{2}{*}{Potassium (K+;mEq/l)} & Admission & 3.9 $\pm$ 0.5 & 3.9 $\pm$ 0.5 & 3.9 $\pm$ 0.4 \\
\hline
Day 1 & 4.1 $\pm$ 0.3* & 4.0 $\pm$ 0.4* & 3.9 $\pm$ 0.4 \\
\hline
\multirow{2}{*}{Temperature (Β°C)} & Admission & 35.2 $\pm$ 0.9 & 34.5 $\pm$ 0.9 & 35.4 $\pm$ 1.2# \\
\hline
Day 1 & 36.6 $\pm$ 0.6 & 36.7 $\pm$ 0.5 & 36.8 $\pm$ 0.5 \\
\hline
\multirow{2}{*}{WBC (103/mm3)} & Admission & 10.8 $\pm$ 4.2 & 12.5 $\pm$ 5.5 & 10.8 $\pm$ 5.1 \\
\hline
Day 1 & 9.4 $\pm$ 3.0* & 10.4 $\pm$ 4.0 & 10.2 $\pm$ 2.7 \\
\hline
\multirow{2}{*}{SIRS criteria} & Admission & 1.4 $\pm$ 0.7 & 1.8 $\pm$ 0.8 & 1.4 $\pm$ 0.9 \\
\hline
Day 1 & 0.9 $\pm$ 0.9* & 1.3 $\pm$ 1.1* & 0.9 $\pm$ 0.8 \\
\hline
\end{tabular}
\end{table} | PMC2717474_table_1 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Low} & \textbf{Intermediate} & \textbf{High} \\
\hline
Number of patients (n) & 34 & 10 & 10 \\
\hline
Age (years) & 69 $\pm$ 15 & 67 $\pm$ 8 & 67 $\pm$ 12 \\
\hline
Duration of surgery (min) & 174 $\pm$ 101 & 183 $\pm$ 73 & 189 $\pm$ 86 \\
\hline
Arterial pressure β OR (mmHg) & 121 $\pm$ 11 & 118 $\pm$ 13 & 123 $\pm$ 11 \\
\hline
Arterial pressure β Preop (mmHg) & 136 $\pm$ 17 & 140 $\pm$ 14 & 135 $\pm$ 11 \\
\hline
pH & 7.388 $\pm$ 0.05 & 7.420 $\pm$ 0.05 & 7.392 $\pm$ 0.04 \\
\hline
BE & -0.9 $\pm$ 2.5 & -0.6 $\pm$ 1.9 & -0.4 $\pm$ 2.4 \\
\hline
Urine output (ml/h) & 239 $\pm$ 193 & 331 $\pm$ 346 & 181 $\pm$ 98 \\
\hline
Cristalloids (mL) & 3045 $\pm$ 1590 & 2895 $\pm$ 917 & 3078 $\pm$ 900 \\
\hline
Colloids (mL) & 580 $\pm$ 280 & 533 $\pm$ 57 & 500 $\pm$ 0 \\
\hline
Blood transfusion (n) & 5 & 1 & 1 \\
\hline
PaO2/FiO2 (mmHg) & 307 $\pm$ 141 & 275 $\pm$ 193 & 243 $\pm$ 145 \\
\hline
Tidal volume (mL) & 679 $\pm$ 102 & 667 $\pm$ 129 & 715 $\pm$ 109 \\
\hline
Respiratory rate (bpm) & 9.9 $\pm$ 1.5 & 9.8 $\pm$ 0.6 & 9.9 $\pm$ 1.1 \\
\hline
Peak airway pressure (cmH2O) & 23.8 $\pm$ 6.3 & 20.8 $\pm$ 5.9 & 24.3 $\pm$ 6.2 \\
\hline
PEEP (cmH2O) & 2.4 $\pm$ 2.3 & 0.9 $\pm$ 2.1 & 3.5 $\pm$ 2.4 * \\
\hline
Invasiveness (n) & 5.1 $\pm$ 1.1 & 5.4 $\pm$ 0.8 & 5.4 $\pm$ 0.8 \\
\hline
Contaminated surgery (n) & 2 & - & - \\
\hline
\end{tabular}
\end{table} | PMC2717474_table_2 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{EA level} & \textbf{Age} & \textbf{Surgery} & \textbf{APACHE} & \textbf{SIRS} & \textbf{Gram +} & \textbf{Gram -} & \textbf{Other} & \textbf{Time} & \textbf{ICU} & \textbf{Hosp} & \textbf{Alive} \\
\hline
0.140 & 77 & A & 11 & 2 & & Klebsiella & & Late & 4 & 20 & Y \\
\hline
0.446 & 50 & T & 6 & 2 & & & Candida & Late & 1 & 6 & Y \\
\hline
0.432 & 73 & O & 13 & 2 & & Contaminants & & Late & 2 & 6 & Y \\
\hline
0.125 & 78 & A & 9 & 2 & & Pseudomonas & & Late & 24 & 26 & Y \\
\hline
0.333 & 71 & A & 9 & 1 & S. epidermidis & & & Early & 1 & 12 & Y \\
\hline
0.235 & 43 & A & 10 & 2 & S. aureus & & & Early & 2 & 12 & Y \\
\hline
0.330 & 90 & O & 11 & 2 & & Enterobacter & & Early & 1 & 32 & Y \\
\hline
0.191 & 72 & A & 10 & 2 & S. aureus & & & Early & 8 & 19 & Y \\
\hline
0.558 & 59 & T & 4 & 2 & & Pseudomonas & & Early & 5 & 9 & Y \\
\hline
0.498 & 36 & O & 3 & 3 & Enterococcus & & & Early & 5 & 19 & Y \\
\hline
0.750 & 78 & A & 7 & 1 & & Pseudomonas & & Early & 28 & - & N \\
\hline
0.825 & 67 & A & 13 & 3 & & Morganella M & & Late & 22 & - & N \\
\hline
0.740 & 76 & T & 8 & 1 & & Klebsiella & & Late & 7 & 29 & Y \\
\hline
\end{tabular}
\end{table} | PMC2717474_table_3 |
|
\begin{table}
\centering
\label{tab:tablelabel}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{DrotAA n = 882} & \textbf{Non-DrotAA n = 11,610} & \textbf{Total n = 12,492} & \textbf{P value} \\
\hline
Gender (male), n (\%) & 511 (57.9) & 6903 (59.5) & 7414 (59.3) & 0.38 \\
\hline
Age, years & 57.6 ($\pm$ 16.8) & 60.6 ($\pm$ 17.5) & 60.3 ($\pm$ 17.5) & <0.001 \\
\hline
Ethnicity, n (\%): & (n = 777) & (n = 10,247) & (n = 11,204) & <0.001 \\
\hline
Caucasian & 479 (61.6) & 4933 (47.3) & 5412 (48.3) \\
\hline
Hispanic & 127 (16.3) & 2353 (22.6) & 2480 (22.1) \\
\hline
East/South East Asia & 55 (7.1) & 2091 (20.1) & 2146 (19.2) \\
\hline
Other & 48 (6.2) & 283 (2.7) & 331 (3.0) \\
\hline
African descent & 40 (5.1) & 194 (1.9) & 234 (2.1) \\
\hline
Western Asia & 28 (3.6) & 573 (5.5) & 601 (5.4) \\
\hline
Region, n (\%): & (n = 882) & (n = 11,610) & (n = 12,492) & <0.001 \\
\hline
US/Canada & 307 (34.8) & 1666 (14.3) & 1973 (15.8) \\
\hline
European Union & 187 (21.2) & 2492 (21.5) & 2679 (21.4) \\
\hline
Other & 388 (44.0) & 7452 (64.2) & 7840 (62.8) \\
\hline
Referral pattern, n (\%): & (n = 876) & (n = 11,535) & (n = 12,410) & <0.001 \\
\hline
ICU transfer from ER & 238 (27.2) & 2522 (21.9) & 2760 (22.2) \\
\hline
ICU transfer from ward & 206 (23.5) & 3214 (27.9) & 3420 (27.6) \\
\hline
ICU transfer from OR & 156 (17.8) & 2408 (20.9) & 2564 (20.7) \\
\hline
ICU transfer from other hospital & 143 (16.3) & 1515 (13.1) & 1658 (13.4) \\
\hline
ICU transfer from other ICU & 47 (5.4) & 338 (2.9) & 385 (3.1) \\
\hline
Direct to ICU from community & 40 (4.6) & 790 (6.8) & 830 (6.7) \\
\hline
Direct to ICU from intermediate care & 40 (4.6) & 654 (5.7) & 694 (5.6) \\
\hline
ICU transfer from another chronic care facility & 4 (0.5) & 51 (0.4) & 55 (0.4) \\
\hline
Other/unknown & 2 (0.2) & 42 (0.4) & 44 (0.4) \\
\hline
\end{tabular}
\end{table} | PMC2717475_table_0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.